

# CITATION REPORT

List of articles citing

ESHRE consensus on the definition of poor responseu  
to ovarian stimulation for in vitro fertilization: the  
Bologna criteria

DOI: 10.1093/humrep/der092  
Human Reproduction, 2011, 26, 1616-24.

**Source:** <https://exaly.com/paper-pdf/50430270/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1242	A systematic review of randomized trials for the treatment of poor ovarian responders: is there any light at the end of the tunnel?. <b>2011</b> , 96, 1058-61.e7		152
1241	The value of growth hormone supplements in ART for poor ovarian responders. <b>2011</b> , 96, 1069-76		39
1240	What strategies are the most effective in optimizing IVF outcome in patients with advanced maternal age?. <b>2011</b> , 6, 591-598		1
1239	Comparison of mild ovarian stimulation with conventional ovarian stimulation in poor responders. <b>2011</b> , 38, 159-63		13
1238	Role of combined oral contraceptives in women undergoing assisted reproduction treatment. <b>2011</b> , 6, 495-499		
1237	Is the measurement of anti-Müllerian hormone essential?. <b>2012</b> , 24, 151-7		18
1236	Current world literature. <b>2012</b> , 24, 194-9		
1235	AMH for predicting poor ovarian responders in GnRH antagonist cycles. <i>Human Reproduction</i> , <b>2012</b> , 27, 1876-7; author reply 1877	5.7	3
1234	Treatment strategies in assisted reproduction for the poor responder patient. <b>2012</b> , 162-207		2
1233	The use of AMH to tailor ovarian stimulation for IVF. <b>2012</b> , 131-139		
1232	Poor responders: Is it time to consider changing the nomenclature?. <b>2012</b> , 3, 109-10		
1231	Human chorionic gonadotrophin stimulation test as a predictor of ovarian response and pregnancy in IVF cycles stimulated with GnRH agonist gonadotrophin treatment: a pilot study. <i>Human Reproduction</i> , <b>2012</b> , 27, 1122-9	5.7	1
1230	Best practices of ASRM and ESHRE: a journey through reproductive medicine. <i>Human Reproduction</i> , <b>2012</b> , 27, 3365-79	5.7	16
1229	Reply: The definition of 'poor response'—Bologna criteria. <i>Human Reproduction</i> , <b>2012</b> , 27, 627-628	5.7	3
1228	Reply: The Bologna criteria for poor ovarian response; has the job been accomplished?. <i>Human Reproduction</i> , <b>2012</b> , 27, 1875-1876	5.7	5
1227	The Bologna criteria for poor ovarian response; has the job been accomplished?. <i>Human Reproduction</i> , <b>2012</b> , 27, 1874-5; author reply 1875-6	5.7	35
1226	The definition of 'poor response': Bologna criteria. <i>Human Reproduction</i> , <b>2012</b> , 27, 626-7; author reply 627-8	5.7	13

1225	A new ovarian response prediction index (ORPI): implications for individualised controlled ovarian stimulation. <b>2012</b> , 10, 94		19
1224	DHEA for poor responders: can treatment be justified in the absence of evidence?. <b>2012</b> , 25, 103-7		9
1223	Ovarian stimulation protocols in assisted reproductive technology: an update. <b>2012</b> , 7, 319-330		4
1222	Live birth rates following natural cycle IVF in women with poor ovarian response according to the Bologna criteria. <i>Human Reproduction</i> , <b>2012</b> , 27, 3481-6	5.7	88
1221	DHEA supplementation improves follicular microenvironment in poor responder patients. <b>2012</b> , 28, 669-73		30
1220	Random anti-Müllerian hormone predicts ovarian response in women with high baseline follicle-stimulating hormone levels : anti-Müllerian hormone in poor responders in assisted reproductive treatment. <b>2012</b> , 29, 797-802		8
1219	Efficacy of low dose hCG on oocyte maturity for ovarian stimulation in poor responder women undergoing intracytoplasmic sperm injection cycle: a randomized controlled trial. <b>2012</b> , 29, 1213-20		5
1218	Best practices of ASRM and ESHRE: a journey through reproductive medicine. <b>2012</b> , 98, 1380-94		42
1217	Ovarian stimulation and intrauterine insemination in women aged 40 years or more. <b>2012</b> , 24, 170-3		18
1216	Anti-Müllerian hormone for the assessment of ovarian response in GnRH-antagonist-treated oocyte donors. <b>2012</b> , 24, 532-9		14
1215	Hype or hope? Ethical and practical considerations with clinical research in women with diminished ovarian reserve. <b>2012</b> , 25, 98-102		4
1214	Effects of transdermal testosterone in poor responders undergoing IVF: systematic review and meta-analysis. <b>2012</b> , 25, 450-9		39
1213	ICSI increases ongoing pregnancy rates in patients with poor response cycle: multivariate analysis of 2819 cycles. <b>2012</b> , 25, 635-41		9
1212	Anti-Müllerian hormone and antral follicle count as predictors of ovarian reserve and successful IVF. <b>2012</b> , 1, 89-92		1
1211	Comparison of IVF outcomes using conventional insemination and ICSI in ovarian cycles in which only one or two oocytes are obtained. <b>2012</b> , 41, 650-6		8
1210	The use of androgens or androgen-modulating agents in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. <b>2012</b> , 18, 127-45		99
1209	The impact of androgen metabolism and FMR1 genotypes on pregnancy potential in women with dehydroepiandrosterone (DHEA) supplementation. <i>Human Reproduction</i> , <b>2012</b> , 27, 3287-93	5.7	25
1208	Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles. <b>2012</b> , 119, 1171-9		79

1207	Synchronization of ovarian stimulation with follicle wave emergence in patients undergoing in vitro fertilization with a prior suboptimal response: a randomized, controlled trial. <b>2012</b> , 98, 881-7.e1-2	11
1206	Clomiphene citrate versus high doses of gonadotropins for in vitro fertilisation in women with compromised ovarian reserve: a randomised controlled non-inferiority trial. <b>2012</b> , 10, 114	23
1205	Ovulation Stimulation and Cycle Management in IVF. <b>2012</b> , 31-53	
1204	In vitro fertilisation treatment and factors affecting success. <b>2012</b> , 26, 777-88	29
1203	Increasing the Stimulation Dose of rFSH in Unexpected Poor Responders Is Not Associated with Better IVF Outcome. <b>2012</b> , 2012, 1-5	99
1202	A chromosome 19 locus positively influences the number of retrieved oocytes during stimulated cycles in Brazilian women. <b>2012</b> , 29, 443-9	6
1201	Improved pregnancy rates with luteinizing hormone supplementation in patients undergoing ovarian stimulation for IVF. <b>2012</b> , 29, 579-83	7
1200	Efficacy of dehydroepiandrosterone to improve ovarian response in women with diminished ovarian reserve: a meta-analysis. <b>2013</b> , 11, 44	67
1199	Does hormonal contraception prior to in vitro fertilization (IVF) negatively affect oocyte yields? A pilot study. <b>2013</b> , 11, 28	16
1198	Can cycle day 7 FSH concentration during controlled ovarian stimulation be used to guide FSH dosing for in vitro fertilization?. <b>2013</b> , 11, 12	2
1197	Individualization of the FSH starting dose in IVF/ICSI cycles using the antral follicle count. <b>2013</b> , 6, 11	44
1196	In vitro fertilization versus conversion to intrauterine insemination in the setting of three or fewer follicles: how should patients proceed when follicular response falls short of expectation?. <b>2013</b> , 100, 94-9	17
1195	In vitro fertilization stimulation protocol for normal responder patients. <b>2013</b> , 29, 109-12	8
1194	The significance of serum anti-Müllerian hormone (AMH) levels in patients over age 40 in first IVF treatment. <b>2013</b> , 30, 821-5	21
1193	Effect of micro-vibration culture system on embryo development. <b>2013</b> , 30, 835-41	25
1192	Antral follicle count determines poor ovarian response better than anti-Müllerian hormone but age is the only predictor for live birth in in vitro fertilization cycles. <b>2013</b> , 30, 657-65	82
1191	Cumulative live birth rate after three ovarian stimulation IVF cycles for poor ovarian responders according to the bologna criteria. <b>2013</b> , 33, 418-422	17
1190	Recurrent IVF failure is associated with elevated progesterone on the day of hCG administration. <b>2013</b> , 171, 78-83	20

1189	Outcome from consecutive ICSI cycles in patients treated with recombinant human LH and those supplemented with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol. <b>2013</b> , 29, 430-5		13
1188	A contagem dos folículos antrais na predição de resultados em ciclos de fertilização in vitro: uma revisão sistemática. <b>2013</b> , 28, 68-73		2
1187	Dehydroepiandrosterone supplementation improves predictive markers for diminished ovarian reserve: serum AMH, inhibin B and antral follicle count. <b>2013</b> , 169, 257-60		41
1186	GnRH antagonist versus long GnRH agonist protocol in poor IVF responders: a randomized clinical trial. <b>2013</b> , 166, 43-6		22
1185	The association between poor ovarian response and thrombophilia in assisted reproduction. <b>2013</b> , 166, 65-9		7
1184	Using the ovarian sensitivity index to define poor, normal, and high response after controlled ovarian hyperstimulation in the long gonadotropin-releasing hormone-agonist protocol: suggestions for a new principle to solve an old problem. <b>2013</b> , 100, 1270-6		52
1183	Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study. <i>Human Reproduction</i> , <b>2013</b> , 28, 1254-60	5-7	33
1182	Predictors of ovarian response in women treated with corifollitropin alfa for in vitro fertilization/intracytoplasmic sperm injection. <b>2013</b> , 100, 430-7		41
1181	Neue Aspekte der ovariellen Stimulation. <b>2013</b> , 46, 890-895		1
1180	The clinical characteristics of women with recurrent implantation failure. <b>2013</b> , 33, 494-8		15
1179	Is AMH useful to reduce low ovarian response to GnRH antagonist protocol in oocyte donors?. <b>2013</b> , 29, 754-7		5
1178	Conventional IVF as a laboratory strategy to rescue fertility potential in severe poor responder patients: the impact of reproductive aging. <b>2013</b> , 29, 997-1001		8
1177	Lipid profiling of follicular fluid from women undergoing IVF: young poor ovarian responders versus normal responders. <b>2013</b> , 16, 269-77		24
1176	Hypoandrogenism in association with diminished functional ovarian reserve. <i>Human Reproduction</i> , <b>2013</b> , 28, 1084-91	5-7	73
1175	The follicular hormonal profile in low-responder patients undergoing unstimulated cycles: Is it hypoandrogenic?. <i>Human Reproduction</i> , <b>2013</b> , 28, 224-9	5-7	24
1174	IVF outcome in poor responders failing to produce viable embryos in the preceding cycle. <b>2013</b> , 26, 569-76		8
1173	Flexible ovarian stimulation in a poor responder: a case report and literature review. <b>2013</b> , 26, 378-83		21
1172	Assessment of theca cell function: a prerequisite to androgen or luteinizing hormone supplementation in poor responders. <b>2013</b> , 99, 333-6		4

1171	Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization-intracytoplasmic sperm injection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study. <b>2013</b> , 100, 438-44	19
1170	Age-related normogram for antral follicle count in women with polycystic ovary syndrome. <b>2013</b> , 27, 414-8	16
1169	Predicting live birth chances for women with multiple consecutive failing IVF cycles: a simple and accurate prediction for routine medical practice. <b>2013</b> , 11, 1	39
1168	Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: an observational pilot study. <b>2013</b> , 99, 422-6	37
1167	Prospective analysis of ovarian reserve markers as determinant in response to controlled ovarian stimulation in women undergoing IVF cycles in low resource setting in India. <b>2013</b> , 288, 697-703	5
1166	Recombinant Luteinizing Hormone supplementation in poor responders undergoing IVF: a systematic review and meta-analysis. <b>2013</b> , 29, 278-84	14
1165	Corifollitropin followed by menotropin for poor ovarian responders' trial (COMPORT): a protocol of a multicentre randomised trial. <b>2013</b> , 3,	9
1164	Can anti-Müllerian hormone be predictive of spontaneous onset of pregnancy in women with unexplained infertility?. <b>2013</b> , 33, 857-61	15
1163	The IVF Outcome Counseling Based on the Model Combining DHEAS and Age in Patients with Low AMH Prior to the First Cycle of GnRH Antagonist Protocol of Ovarian Stimulation. <b>2013</b> , 2013, 637919	6
1162	Cycle cancellation and pregnancy after luteal estradiol priming in women defined as poor responders: a systematic review and meta-analysis. <i>Human Reproduction</i> , <b>2013</b> , 28, 2981-9	5-7 38
1161	Biennial Review of Infertility. <b>2013</b> ,	1
1160	Pratique de la stimulation ovulatoire par les gonadotrophines. <b>2013</b> ,	0
1159	La stimulation multifolliculaire. <b>2013</b> , 143-174	
1158	Factors associated with failed treatment: an analysis of 121,744 women embarking on their first IVF cycles. <b>2013</b> , 8, e82249	56
1157	Ovarian response and cumulative live birth rate of women undergoing in-vitro fertilisation who had discordant anti-Müllerian hormone and antral follicle count measurements: a retrospective study. <b>2014</b> , 9, e108493	16
1156	Comparison of IVF Outcomes between Minimal Stimulation and High-Dose Stimulation for Patients with Poor Ovarian Reserve. <b>2014</b> , 2014, 581451	24
1155	Management of poor responders in IVF: is there anything new?. <b>2014</b> , 2014, 352098	84
1154	The effect of aromatase inhibitor letrozole incorporated in gonadotrophin-releasing hormone antagonist multiple dose protocol in poor responders undergoing in vitro fertilization. <b>2014</b> , 57, 216-22	7

1153	Subclinical hypothyroidism diagnosed by thyrotropin-releasing hormone stimulation test in infertile women with basal thyroid-stimulating hormone levels of 2.5 to 5.0 mIU/L. <b>2014</b> , 57, 507-12		3
1152	ESR1 and FSHR Gene Polymorphisms Influence Ovarian Response to FSH in Poor Responder Women with Normal FSH Levels. <b>2014</b> , 03,		2
1151	Handbook of diet and nutrition in the menstrual cycle, periconception and fertility. <b>2014</b> ,		5
1150	Reply: The two sides of the individualization of controlled ovarian stimulation. <b>2014</b> , 20, 614-5		2
1149	The Bologna criteria for the definition of poor ovarian responders: is there a need for revision?. <i>Human Reproduction</i> , <b>2014</b> , 29, 1842-5	5-7	80
1148	The association between embryo quality and perinatal outcome of singletons born after single embryo transfers: a pilot study. <i>Human Reproduction</i> , <b>2014</b> , 29, 1444-51	5-7	74
1147	ESR1 and ESR2 gene polymorphisms are associated with human reproduction outcomes in Brazilian women. <b>2014</b> , 7, 114		26
1146	Dehydroepiandrosterone improves follicular fluid bone morphogenetic protein-15 and accumulated embryo score of infertility patients with diminished ovarian reserve undergoing in vitro fertilization: a randomized controlled trial. <b>2014</b> , 7, 93		27
1145	Comparison of estradiol and progesterone priming/antagonist/letrozole and microdose flare-up protocols for poor responders undergoing intracytoplasmic sperm injection. <b>2014</b> , 30, 653-6		8
1144	Which cut-off value of serum anti-Müllerian hormone level can predict poor ovarian reserve, poor ovarian response to stimulation and in vitro fertilization success? A prospective data analysis. <b>2014</b> , 30, 372-6		22
1143	Reproductive function assessment after surgery plus chemotherapy for germ cell ovarian tumors (MOGCT): novel clues deriving from the field of fertility preservation. <b>2014</b> , 30, 778-80		7
1142	LH pretreatment as a novel strategy for poor responders. <b>2014</b> , 2014, 926172		9
1141	Impact of dehydroepiandrosterone on clinical outcome in poor responders: A pilot study in women undergoing in vitro fertilization, using bologna criteria. <b>2014</b> , 7, 175-80		20
1140	Growth hormone and reproduction: a review of endocrine and autocrine/paracrine interactions. <b>2014</b> , 2014, 234014		66
1139	Reference values in ovarian response to controlled ovarian stimulation throughout the reproductive period. <b>2014</b> , 30, 66-9		7
1138	Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. <i>Human Reproduction</i> , <b>2014</b> , 29, 1688-97	5-7	41
1137	The Bologna criteria for poor ovarian response: the good, the bad and the way forward. <i>Human Reproduction</i> , <b>2014</b> , 29, 1839-41	5-7	33
1136	Best protocol for controlled ovarian hyperstimulation in assisted reproductive technologies: fact or opinion?. <b>2014</b> , 32, 262-71		15

1135	Serum anti-mullerian hormone in reproductive aged women with benign ovarian cysts. <b>2014</b> , 180, 142-7	17
1134	Gene expression of cumulus cells in women with poor ovarian response after dehydroepiandrosterone supplementation. <b>2014</b> , 53, 559-65	19
1133	In vitro fertilization versus conversion to intrauterine insemination in Bologna-criteria poor responders: how to decide which option?. <b>2014</b> , 102, 1596-601	11
1132	Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). <b>2014</b> , 29, 684-91	175
1131	The comparison of effect of microdose GnRH-a flare-up, GnRH antagonist/aromatase inhibitor letrozole and GnRH antagonist/clomiphene citrate protocols on IVF outcomes in poor responder patients. <b>2014</b> , 30, 485-9	13
1130	Variant-beta luteinizing hormone is not associated with poor ovarian response to controlled ovarian hyperstimulation. <b>2014</b> , 12, 20	2
1129	Endometrial thickness affects the outcome of in vitro fertilization and embryo transfer in normal responders after GnRH antagonist administration. <b>2014</b> , 12, 96	59
1128	Predictive value of androgens and multivariate model for poor ovarian response. <b>2014</b> , 28, 723-32	10
1127	Transvaginal ovarian trauma, poor responders and improvement of success rates in IVF: anecdotal data and a hypothesis. <b>2014</b> , 83, 227-31	1
1126	Extended embryo culture is not associated with increased adverse obstetric or perinatal outcome. <b>2014</b> , 211, 165.e1-7	26
1125	Long gonadotropin-releasing hormone agonist versus short agonist versus antagonist regimens in poor responders undergoing in vitro fertilization: a randomized controlled trial. <b>2014</b> , 101, 147-53	69
1124	The contribution of sildenafil (Viagra) to ovarian stimulation with gonadotropins in a woman with poor ovarian response. <b>2014</b> , 30, 478-80	5
1123	Kinderwunsch der Frau ab 40 Jahren. <b>2014</b> , 12, 9-15	
1122	A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology. <b>2014</b> , 12, 6	5
1121	The dynamics of serum anti-Mullerian-hormone levels during controlled ovarian hyperstimulation with GnRH-antagonist short protocol in polycystic ovary syndrome and low responders. <b>2014</b> , 176, 163-7	15
1120	Association between response to ovarian stimulation and miscarriage following IVF: an analysis of 124 351 IVF pregnancies. <i>Human Reproduction</i> , <b>2014</b> , 29, 1218-24	5-7 53
1119	A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders. <b>2014</b> , 102, 108-115.e1	65
1118	A novel "delayed start" protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders. <b>2014</b> , 101, 1308-14	27



1117	Recurrent implantation failure: definition and management. <b>2014</b> , 28, 14-38		385
1116	The physiology and clinical utility of anti-Mullerian hormone in women. <b>2014</b> , 20, 370-85		513
1115	Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. <b>2014</b> , 20, 124-40		295
1114	[Early recurrent miscarriage: Evaluation and management]. <b>2014</b> , 43, 812-41		8
1113	Is assessment of anti-Müllerian hormone and/or antral follicle count useful in the prediction of ovarian response in expected normal responders treated with a fixed dose of recombinant FSH and GnRH antagonists? A prospective observational study. <b>2014</b> , 30, 817-21		5
1112	The ovarian response to controlled stimulation in IVF cycles may be predictive of the age at menopause. <i>Human Reproduction</i> , <b>2014</b> , 29, 2530-5	5-7	6
1111	Ovarian reserve screening: a scientific and ethical analysis. <i>Human Reproduction</i> , <b>2014</b> , 29, 2606-14	5-7	46
1110	Implementing the ESHRE 'poor responder' criteria in research studies: methodological implications. <i>Human Reproduction</i> , <b>2014</b> , 29, 1835-8	5-7	62
1109	Counting ovarian follicles: updated threshold for diagnosis of hyperandrogenic anovulation. <b>2014</b> , 44, 131-4		16
1108	Recombinant LH administration in subsequent cycle after "unexpected" poor response to recombinant FSH monotherapy. <b>2014</b> , 30, 813-6		11
1107	Androgen receptor CAG repeat length is associated with ovarian reserve but not with ovarian response. <b>2014</b> , 29, 509-15		5
1106	Association between intrafollicular concentration of benzene and outcome of controlled ovarian stimulation in IVF/ICSI cycles: a pilot study. <b>2014</b> , 7, 67		27
1105	Vitamin D deficiency and infertility: insights from in vitro fertilization cycles. <b>2014</b> , 99, E2372-6		86
1104	Ovarielle Stimulation bei der prÜund perimenopausalen Patientin. <b>2014</b> , 47, 258-262		
1103	"Mild" vs. "long" protocol for controlled ovarian hyperstimulation in patients with expected poor ovarian responsiveness undergoing in vitro fertilization (IVF): a large prospective randomized trial. <b>2014</b> , 31, 809-15		58
1102	Genetic associations with diminished ovarian reserve: a systematic review of the literature. <b>2014</b> , 31, 935-46		50
1101	Impact of endometriosis and its staging on assisted reproduction outcome: systematic review and meta-analysis. <b>2014</b> , 44, 261-78		67
1100	Live birth rates in Bologna poor responders treated with ovarian stimulation for IVF/ICSI. <b>2014</b> , 28, 469-74		81

1099	Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis. <b>2014</b> , 12, 17	86
1098	Low-dosage clomiphene reduces premature ovulation rates and increases transfer rates in natural-cycle IVF. <b>2014</b> , 29, 209-15	32
1097	Dehydroepiandrosterone sulphate and prediction of live birth after IVF in young women with low anti-Müllerian hormone concentration. <b>2014</b> , 28, 191-7	3
1096	Effectiveness of the antagonist/letrozole protocol for treating poor responders undergoing in vitro fertilization/intracytoplasmic sperm injection: a systematic review and meta-analysis. <b>2014</b> , 30, 330-4	15
1095	Luteal phase support with estrogen in addition to progesterone increases pregnancy rates in in vitro fertilization cycles with poor response to gonadotropins. <b>2014</b> , 30, 363-6	14
1094	Poor responders and androgen adjuvant treatment: "Still haven't found what I'm looking for...". <b>2014</b> , 28, 661-2	4
1093	Is the modified natural in vitro fertilization cycle justified in patients with "genuine" poor response to controlled ovarian hyperstimulation?. <b>2014</b> , 101, 1624-8	32
1092	26. Nutraceutical approaches in female infertility: setting the rationale for treatments tailored to the patient's phenotype and based on selected molecules. <b>2014</b> , 413-430	
1091	Strategies for Controlled Ovarian Stimulation in the Setting of Ovarian Aging. <b>2015</b> , 33, 436-48	4
1090	Addition of growth hormone to the microflare stimulation protocol among women with poor ovarian response. <b>2015</b> , 131, 305-8	29
1089	The role of genetic and autoimmune factors in poor ovarian response in IVF programs. <b>2015</b> , 31, 65-68	
1088	Recombinant LH supplementation during IVF cycles with a GnRH-antagonist in estimated poor responders: A cross-matched pilot investigation of the optimal daily dose and timing. <b>2015</b> , 12, 4219-4229	18
1087	Pretreatment with oral contraceptive pills to identify poor responders that may benefit from rLH supplementation during GnRH-antagonist treatment for IVF: A pilot perspective study proposal. <b>2015</b> , 10, 1692-1696	1
1086	A poor responder. 63-66	
1085	Ovarian response is a better predictor of clinical pregnancy rate following embryo transfer than is thin endometrium or presence of an endometrioma. <b>2015</b> , 46, 501-5	14
1084	Growth Hormone Supplementation in the Luteal Phase Before Microdose GnRH Agonist Flare Protocol for In Vitro Fertilization. <b>2015</b> , 37, 810-815	14
1083	Predictive value of age-specific FSH levels for IVF-ET outcome in women with normal ovarian function. <b>2015</b> , 13, 63	11
1082	Anti-Müllerian hormone as a predictor of ovarian reserve in ART protocols: the hidden role of thyroid autoimmunity. <b>2015</b> , 13, 106	16

1081	The Bologna criteria for poor ovarian response: a contemporary critical appraisal. <b>2015</b> , 8, 76		57
1080	Serum anti-Müllerian hormone in subfertile women. <b>2015</b> , 94, 1307-12		18
1079	What number of oocytes is appropriate for defining poor ovarian response?. <b>2015</b> , 56, 482-9		10
1078	Predictive Value of AMH, FSH and AFC for Determining Ovarian Response in Vietnamese Women Undergoing Assisted Reproductive Technologies: A Prospective Study. <b>2015</b> , 03,		
1077	Effect of early endometriosis on ovarian reserve and reproductive outcome. <b>2015</b> , 7, 40-5		1
1076	Novel dehydroepiandrosterone troche supplementation improves the serum androgen profile of women undergoing in vitro fertilization. <b>2015</b> , 9, 5569-78		7
1075	High Prevalence of Vitamin D Deficiency in Infertile Women Referring for Assisted Reproduction. <b>2015</b> , 7, 9972-84		41
1074	Live birth and cumulative live birth rates in expected poor ovarian responders defined by the Bologna criteria following IVF/ICSI treatment. <b>2015</b> , 10, e0119149		14
1073	A Flexible Multidose GnRH Antagonist versus a Microdose Flare-Up GnRH Agonist Combined with a Flexible Multidose GnRH Antagonist Protocol in Poor Responders to IVF. <b>2015</b> , 2015, 970163		3
1072	The Role of Overweight and Obesity in In Vitro Fertilization Outcomes of Poor Ovarian Responders. <b>2015</b> , 2015, 781543		14
1071	The Prognosis of IVF in Poor Responders Depending on the Bologna Criteria: A Large Sample Retrospective Study from China. <b>2015</b> , 2015, 296173		7
1070	Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. <i>Human Reproduction</i> , <b>2015</b> , 30, 1188-95	5.7	31
1069	Prognostic factors for IVF success: diagnostic testing and evidence-based interventions. <b>2015</b> , 33, 65-76		10
1068	Definitions and Relevance of Unexplained Infertility in Reproductive Medicine. <b>2015</b> , 3-5		6
1067	Live birth rates in the different combinations of the Bologna criteria poor ovarian responders: a validation study. <b>2015</b> , 32, 931-7		62
1066	Clinical application of dehydroepiandrosterone in reproduction: A review of the evidence. <b>2015</b> , 78, 446-53		14
1065	Obesity and Fertility. <b>2015</b> ,		1
1064	The necessity to define the sub-optimal responders. <i>Human Reproduction</i> , <b>2015</b> , 30, 2958	5.7	3

1063	Vitrification Is the Keystone to Minimal Stimulation IVF. <b>2015</b> , 87-94		
1062	Committee opinion no. 618: Ovarian reserve testing. <b>2015</b> , 125, 268-273		79
1061	A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation. <b>2015</b> , 54, 583-7		3
1060	Fertilization failure after IVF in 304 couples--a case-control study on predictors and long-term prognosis. <b>2015</b> , 184, 32-7		14
1059	Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial. <i>Human Reproduction</i> , <b>2015</b> , 30, 432-40	5-7	32
1058	Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response. <b>2015</b> , 21, 698-710		131
1057	Testing and interpreting measures of ovarian reserve: a committee opinion. <b>2015</b> , 103, e9-e17		213
1056	Single nucleotide polymorphisms in the Anti-Müllerian hormone (AMH Ile(49)Ser) and Anti-Müllerian hormone type II receptor (AMHRII -482 A>G) as genetic markers in assisted reproduction technology. <b>2015</b> , 32, 357-67		15
1055	Poor responders in IVF: an update in therapy. <b>2015</b> , 31, 253-7		16
1054	Surgical diminished ovarian reserve after endometrioma cystectomy versus idiopathic DOR: comparison of in vitro fertilization outcome. <i>Human Reproduction</i> , <b>2015</b> , 30, 840-7	5-7	46
1053	What is the value of anti-Müllerian hormone in predicting the response to ovarian stimulation with GnRH agonist and antagonist protocols?. <b>2015</b> , 13, 58		12
1052	Myo-inositol therapy for poor-responders during IVF: a prospective controlled observational trial. <b>2015</b> , 8, 37		17
1051	Mild ovarian stimulation with clomiphene citrate launch is a realistic option for in vitro fertilization. <b>2015</b> , 104, 333-8		26
1050	Ovulation Stimulation with Gonadotropins. <b>2015</b> ,		1
1049	Clinical issues during ART. <b>2015</b> , 275-289		
1048	Performance of the two new fully automated anti-Müllerian hormone immunoassays compared with the clinical standard assay. <i>Human Reproduction</i> , <b>2015</b> , 30, 1918-26	5-7	59
1047	Delayed Start Versus Conventional GnRH Antagonist Protocol in Poor Responders Pretreated With Estradiol in Luteal Phase: A Randomized Controlled Trial. <b>2015</b> , 22, 1627-31		7
1046	AntiMüllerian hormone as a predictor of good-quality supernumerary blastocyst cryopreservation among women with levels . <b>2015</b> , 104, 633-6		10

1045	Efficacy and Safety of Pergoveris in Assisted Reproductive Technology--ESPART: rationale and design of a randomised controlled trial in poor ovarian responders undergoing IVF/ICSI treatment. <b>2015</b> , 5, e008297	7
1044	Corifollitropin alfa followed by hpHMG in GnRH agonist protocols. Two prospective feasibility studies in poor ovarian responders. <b>2015</b> , 31, 885-90	16
1043	Outcomes of 1503 cycles of modified natural cycle in vitro fertilization: a single-institution experience. <b>2015</b> , 32, 1043-8	12
1042	Diminished ovarian reserve in the United States assisted reproductive technology population: diagnostic trends among 181,536 cycles from the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System. <b>2015</b> , 104, 612-19.e3	74
1041	Are good patient and embryo characteristics protective against the negative effect of elevated progesterone level on the day of oocyte maturation?. <b>2015</b> , 103, 1477-84.e1-5	54
1040	Does ovarian reserve predict egg quality in unstimulated therapeutic donor insemination cycles?. <b>2015</b> , 103, 1170-5.e2	21
1039	Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. <b>2015</b> , 30, 248-57	35
1038	Effects of dehydroepiandrosterone supplementation on women with poor ovarian response: A preliminary report and review. <b>2015</b> , 54, 131-6	19
1037	Do poor-responder patients benefit from increasing the daily gonadotropin dose during controlled ovarian hyperstimulation for IVF?. <b>2015</b> , 31, 79-82	16
1036	Prediction of Poor Ovarian response by Biochemical and Biophysical Markers: A Logistic Regression Model. <b>2015</b> , 65, 411-6	5
1035	Menstrual cycle length: a surrogate measure of reproductive health capable of improving the accuracy of biochemical/sonographical ovarian reserve test in estimating the reproductive chances of women referred to ART. <b>2015</b> , 13, 28	21
1034	A direct action for GH in improvement of oocyte quality in poor-responder patients. <b>2015</b> , 149, 147-54	36
1033	How to define, diagnose and treat poor responders? Responses from a worldwide survey of IVF clinics. <b>2015</b> , 30, 581-92	70
1032	Prospective study into the value of the automated Elecsys antimüllerian hormone assay for the assessment of the ovarian growing follicle pool. <b>2015</b> , 103, 1074-1080.e4	54
1031	Live birth rates using conventional in vitro fertilization compared to intracytoplasmic sperm injection in Bologna poor responders with a single oocyte retrieved. <b>2015</b> , 32, 691-7	27
1030	Poor ovarian response in women undergoing in vitro fertilization is associated with altered microRNA expression in cumulus cells. <b>2015</b> , 103, 1469-76.e1-3	34
1029	Can serum estradiol levels on the fourth day of IVF/ICSI cycle predict outcome in poor responder women?. <b>2015</b> , 61, 233-7	4
1028	Comparison of human menopausal gonadotropin stimulation with and without clomiphene for in-vitro fertilisation in poor-responders. <b>2015</b> , 35, 163-7	10

1027	A retrospective evaluation of prognosis and cost-effectiveness of IVF in poor responders according to the Bologna criteria. <i>Human Reproduction</i> , <b>2015</b> , 30, 315-22	5-7	84
1026	Comparison of reproductive outcome in oligozoospermic men with high sperm DNA fragmentation undergoing intracytoplasmic sperm injection with ejaculated and testicular sperm. <b>2015</b> , 104, 1398-405		123
1025	Controlled Ovarian Stimulation for Follicular Recruitment and Oocyte Recovery in IVF. <b>2015</b> , 21-31		
1024	Triggering final follicular maturation--hCG, GnRH-agonist or both, when and to whom?. <b>2015</b> , 8, 60		48
1023	Principles and Practice of Controlled Ovarian Stimulation in ART. <b>2015</b> ,		2
1022	A pilot study to evaluate a device for the intravaginal culture of embryos. <b>2015</b> , 31, 732-8		3
1021	Term pregnancy and live birth subsequent to immediate uterine transfer of sperm microinjected oocyte in a natural cycle. <b>2015</b> , 31, 599-600		2
1020	Shifting paradigms in diminished ovarian reserve and advanced reproductive age in assisted reproduction: customization instead of conformity. <b>2015</b> , 33, 169-78		17
1019	Antral Follicle Priming Before Intracytoplasmic Sperm Injection in Previously Diagnosed Low Responders: A Randomized Controlled Trial (FOLLPRIM). <b>2015</b> , 100, 2597-605		3
1018	Diminished ovarian reserve, premature ovarian failure, poor ovarian responder--a plea for universal definitions. <b>2015</b> , 32, 1709-12		87
1017	Association between anti-chlamydial immunity and IVF outcome. <b>2015</b> , 31, 69-73		3
1016	Minimal Stimulation and Natural Cycle In Vitro Fertilization. <b>2015</b> ,		
1015	A meta-analysis of dehydroepiandrosterone supplementation among women with diminished ovarian reserve undergoing in vitro fertilization or intracytoplasmic sperm injection. <b>2015</b> , 131, 240-5		33
1014	Niveles sfcicos de hormona antimulleriana como predictor de baja respuesta en mujeres sometidas a ciclos de fecundaci3n in vitro. <b>2015</b> , 2, 9-16		1
1013	Sub-optimal responders following controlled ovarian stimulation: an overlooked group?. <i>Human Reproduction</i> , <b>2015</b> , 30, 2005-8	5-7	59
1012	BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles. <b>2015</b> , 104, 1162-7		62
1011	Live-birth rates in very poor prognosis patients, who are defined as poor responders under the Bologna criteria, with nonelective single embryo, two-embryo, and three or more embryos transferred. <b>2015</b> , 104, 1435-41		24
1010	Can calcium ionophore "use" in patients with diminished ovarian reserve increase fertilization and pregnancy rates? A randomized, controlled study. <b>2015</b> , 104, 1168-74		16

1009	Vitrification of day 3 cleavage-stage embryos yields better clinical outcome in comparison with vitrification of day 2 cleavage-stage embryos. <b>2015</b> , 23, 169-76	7
1008	Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders. <i>Human Reproduction</i> , <b>2015</b> , 30, 2321-30	5-7 47
1007	Estrogen or anti-estrogen for Bologna poor responders?. <b>2015</b> , 31, 955-8	3
1006	The continuum of high ovarian response: a rational approach to the management of high responder patient subgroups. <b>2015</b> , 61, 336-44	4
1005	Intraovarian control of early folliculogenesis. <b>2015</b> , 36, 1-24	350
1004	Dehydroepiandrosterone administration before IVF in poor responders: a prospective cohort study. <b>2015</b> , 30, 191-6	29
1003	Live birth of twins after performing early hCG administration as a modification of natural cycle in vitro fertilization, in a women with decreased ovarian reserve. <b>2015</b> , 291, 219-22	6
1002	Effectiveness of corifollitropin alfa used for ovarian stimulation of poor responder patients. <b>2016</b> , 8, 609-615	7
1001	The novel POSEIDON stratification of 'Low prognosis patients in Assisted Reproductive Technology' and its proposed marker of successful outcome. <b>2016</b> , 5, 2911	128
1000	Does Unilateral Oocyte Retrieval due to Transvaginally Inaccessible Ovaries, Contrary to Common Beliefs, Affect IVF/ICSI Treatment Outcomes That Much?. <b>2016</b> , 2016, 3687483	
999	Morphokinetic Characteristics and Developmental Potential of In Vitro Cultured Embryos from Natural Cycles in Patients with Poor Ovarian Response. <b>2016</b> , 2016, 4286528	10
998	Comparison of static culture, micro-vibration culture, and micro-vibration culture with co-culture in poor ovarian responders. <b>2016</b> , 43, 146-51	4
997	The meaning of anti-Müllerian hormone levels in patients at a high risk of poor ovarian response. <b>2016</b> , 43, 139-45	7
996	Comparison of ovarian responsiveness tests with outcome of assisted reproductive technology - a retrospective analysis. <b>2018</b> , 14, 851-859	5
995	The association between multinucleated blastomeres and poor ovarian response under the Bologna criteria. <b>2016</b> , 33, 885-92	1
994	An upper limit of gonadotropin dose in patients undergoing ART should be advocated. <b>2016</b> , 32, 965-969	8
993	Excessive Age-Related Decline in Functional Ovarian Reserve in Infertile Women: Prospective Cohort of 15,500 Women. <b>2016</b> , 101, 3548-54	14
992	Clinical Applications of Gonadotropins in the Female: Assisted Reproduction and Beyond. <b>2016</b> , 143, 85-119	20

991	Live birth in a 46-year-old woman using microdose GnRH agonist flare-up protocol combined with GnRH antagonist: a case report. <b>2016</b> , 4, 1107-1111		
990	Evaluation of factors predicting diminished ovarian reserve before and after laparoscopic cystectomy for ovarian endometriomas: a prospective cohort study. <b>2016</b> , 9, 37		16
989	Luteal-phase ovarian stimulation is a feasible method for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment compared to a GnRH antagonist protocol: A retrospective study. <b>2016</b> , 55, 50-4		12
988	Can we modify assisted reproductive technology practice to broaden reproductive care access?. <b>2016</b> , 105, 1138-1143		14
987	A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. <b>2016</b> , 203, 30-4		48
986	A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. <b>2016</b> , 105, 1452-3		221
985	Predicting the success of IVF: external validation of the van Loendersloot's model. <i>Human Reproduction</i> , <b>2016</b> , 31, 1245-52	5-7	10
984	In Estimated Good Prognosis Patients Could Unexpected "Hyporesponse" to Controlled Ovarian Stimulation be Related to Genetic Polymorphisms of FSH Receptor?. <b>2016</b> , 23, 1103-8		26
983	Gonadotrophin-releasing hormone agonist protocol of controlled ovarian hyperstimulation as an efficient treatment in Bologna-defined poor ovarian responders. <b>2016</b> , 62, 290-6		6
982	Effects of traditional Korean medicine on anti-Müllerian hormone in patients with diminished ovarian reserve: A retrospective study. <b>2016</b> , 24, 118-22		10
981	Age, independent from ovarian reserve status, is the main prognostic factor in natural cycle in vitro fertilization. <b>2016</b> , 106, 342-347.e2		30
980	Is FMR1 CGG repeat length a predictor of in vitro fertilization stimulation response or outcome?. <b>2016</b> , 105, 1537-1546.e8		7
979	Dehydroepiandrosterone treatment in women with poor ovarian response undergoing IVF or ICSI: a systematic review and meta-analysis. <b>2016</b> , 33, 981-91		37
978	Preservaci3n de fertilidad en endometriosis: estado actual de conocimiento y papel del sistema p3blico de salud. <b>2016</b> , 3, 119-127		1
977	Tasa acumulada de nacido vivo en pacientes con endometriosis. <b>2016</b> , 3, 144-151		
976	Age related normogram for antral follicle count in general population and comparison with previous studies. <b>2016</b> , 206, 120-124		13
975	A comparison among different methods of letrozole combined with gonadotropin in an antagonist protocol and high-dose gonadotropin ovarian stimulation antagonist protocol in poor ovarian responders undergoing in vitro fertilization. <b>2016</b> , 294, 1091-1097		11
974	Correlation of normal-range FMR1 repeat length or genotypes and reproductive parameters. <b>2016</b> , 33, 1149-55		6



973	The impact of FMR1 gene mutations on human reproduction and development: a systematic review. <b>2016</b> , 33, 1135-47		8
972	[Is gonadotropin releasing hormone (GnRH) agonist trigger beneficial or deleterious?]. <b>2016</b> , 44, 403-9		
971	Efficiency of mild ovarian stimulation with clomiphene on poor ovarian responders during IVF/ICSI procedures: a meta-analysis. <b>2016</b> , 204, 36-43		33
970	Association of a promoter polymorphism in FSHR with ovarian reserve and response to ovarian stimulation in women undergoing assisted reproductive treatment. <b>2016</b> , 33, 391-7		13
969	Does poor ovarian response to gonadotrophins predict early menopause? A retrospective cohort study with minimum of 10-year follow-up. <b>2016</b> , 19, 212-9		9
968	Endometriosis has no negative impact on outcomes of in vitro fertilisation in women with poor ovarian response. <b>2016</b> , 123 Suppl 3, 76-81		5
967	Luteal phase support with estradiol and progesterone versus progesterone alone in GnRH antagonist ICSI cycles: a randomized controlled study. <b>2016</b> , 19, 142-9		10
966	Artificial oocyte activation after intracytoplasmic morphologically selected sperm injection: A prospective randomized sibling oocyte study. <b>2016</b> , 19, 282-288		13
965	A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial. <i>Human Reproduction</i> , <b>2017</b> , 32, 112-118	5:7	53
964	A predictive scheme to assess the outcome of IVF/ICSI cycles in poor responders. <b>2016</b> , 6, 90-94		
963	Establishment and adipocyte differentiation of polycystic ovary syndrome-derived induced pluripotent stem cells. <b>2016</b> , 49, 352-61		7
962	Successful use of "Hour 1" transfer of sperm microinjected oocytes in natural cycles of poor responder women: a prospective randomized controlled pilot study. <b>2016</b> , 32, 370-3		1
961	Endometriosis, Ovarian Reserve and Live Birth Rate Following In Vitro Fertilization/Intracytoplasmic Sperm Injection. <b>2016</b> , 38, 218-24		10
960	Dehydroepiandrosterone plus climen supplementation shows better effects than dehydroepiandrosterone alone on infertility patients with diminished ovarian reserve of low-FSH level undergoing in-vitro fertilization cycles: a randomized controlled trial. <b>2016</b> , 14, 9		2
959	Minimum ovarian stimulation involving combined clomiphene citrate and estradiol treatment for in vitro fertilization of Bologna-criteria poor ovarian responders. <b>2016</b> , 42, 178-83		7
958	Adjuvant sildenafil therapy in poor responders undergoing in vitro fertilization: A prospective, randomized, double-blind, placebo-controlled trial. <b>2016</b> , 21, 175-179		5
957	Recurrent implantation failure in IVF: features of cycles that eventually ended in conception. <b>2016</b> , 293, 893-900		7
956	Serum Stem Cell Factor Assay in Elderly Poor Responder Patients Undergoing IVF: A New Biomarker to Customize Follicle Aspiration Cycle by Cycle. <b>2016</b> , 23, 61-8		18

955	Low antimullerian hormone levels may be associated with cardiovascular risk markers in women with diminished ovarian reserve. <b>2016</b> , 32, 302-5		15
954	Transdermal testosterone pretreatment in poor responders undergoing ICSI: a randomized clinical trial. <i>Human Reproduction</i> , <b>2016</b> , 31, 977-85	5-7	37
953	Infertile women below the age of 40 have similar anti-Müllerian hormone levels and antral follicle count compared with women of the same age with no history of infertility. <i>Human Reproduction</i> , <b>2016</b> , 31, 1034-45	5-7	37
952	The effect of LH supplementation to the GnRH antagonist protocol in advanced reproductive ageing women: a prospective randomized controlled study. <b>2016</b> , 84, 99-106		8
951	Usefulness of oocyte accumulation in low ovarian response for PGS. <b>2016</b> , 32, 577-80		6
950	Is there an effect of thyroid autoimmunity on the outcomes of assisted reproduction?. <b>2016</b> , 36, 213-7		22
949	Trends in 'poor responder' research: lessons learned from RCTs in assisted conception. <b>2016</b> , 22, 306-19		56
948	Primary Ovarian Insufficiency. <b>2016</b> ,		4
947	The use of coenzyme Q10 and DHEA during IUI and IVF cycles in patients with decreased ovarian reserve. <b>2016</b> , 32, 534-7		23
946	Does dehydroepiandrosterone improve pregnancy rate in women undergoing IVF/ICSI with expected poor ovarian response according to the Bologna criteria? A randomized controlled trial. <b>2016</b> , 200, 11-5		25
945	Does the addition of growth hormone to the in vitro fertilization/intracytoplasmic sperm injection antagonist protocol improve outcomes in poor responders? A randomized, controlled trial. <b>2016</b> , 105, 697-702		50
944	Multicenter analytical performance evaluation of a fully automated anti-Müllerian hormone assay and reference interval determination. <b>2016</b> , 49, 260-7		59
943	Younger poor ovarian response women achieved better pregnancy results in the first three IVF cycles. <b>2016</b> , 32, 532-7		19
942	Effects of granulocyte-macrophage colony-stimulating factor supplementation in culture medium on embryo quality and pregnancy outcome of women aged over 35 years. <b>2016</b> , 33, 39-47		15
941	Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?. <i>Human Reproduction</i> , <b>2016</b> , 31, 370-6	5-7	196
940	The use of ovarian reserve markers in IVF clinical practice: a national consensus. <b>2016</b> , 32, 1-5		47
939	Frontiers in Gynecological Endocrinology. <b>2016</b> ,		1
938	[Ovarian failure: New treatments in perspective?]. <b>2016</b> , 44, 56-62		1

937	Ovarian Stimulation for Poor Responders. <b>2016</b> , 113-119	
936	Microdose flare protocol with interrupted follicle stimulating hormone and added androgen for poor responders--an observational pilot study. <b>2016</b> , 105, 100-5.e1-6	7
935	[High doses of gonadotropins for controlled ovarian hyperstimulation: A case-control study]. <b>2016</b> , 44, 29-34	3
934	Comparison between follicular stimulation and luteal stimulation protocols with clomiphene and HMG in women with poor ovarian response. <b>2016</b> , 32, 74-7	25
933	Ovarian Stimulation Protocols. <b>2016</b> ,	6
932	Regulatory Principles of Follicular Development. <b>2016</b> , 1-16	2
931	Spontaneous fertility and in vitro fertilization outcome: new evidence of human papillomavirus sperm infection. <b>2016</b> , 105, 65-72.e1	52
930	Which is the best IVF/ICSI protocol to be used in poor responders receiving growth hormone as an adjuvant treatment? A prospective randomized trial. <b>2016</b> , 32, 116-9	13
929	Expression Levels of the Oxidative Stress Response Gene ALDH3A2 in Granulosa-Lutein Cells Are Related to Female Age and Infertility Diagnosis. <b>2016</b> , 23, 604-9	14
928	The effect of dehydroepiandrosterone (DHEA) supplementation on women with diminished ovarian reserve (DOR) in IVF cycle: Evidence from a meta-analysis. <b>2017</b> , 46, 1-7	32
927	Testicular versus ejaculated spermatozoa in ICSI cycles of normozoospermic men with high sperm DNA fragmentation and previous ART failures. <b>2017</b> , 49, e12609	37
926	Melatonin levels in follicular fluid as markers for IVF outcomes and predicting ovarian reserve. <b>2017</b> , 153, 443-451	42
925	Specific ranges of anti-Mullerian hormone and antral follicle count correlate to provide a prognostic indicator for IVF outcome. <b>2017</b> , 17, 51-59	17
924	GnRH antagonist and letrozole co-treatment in diminished ovarian reserve patients: a proof-of-concept study. <b>2017</b> , 17, 105-110	9
923	Impact of Cystectomy on Ovarian Reserve: Review of the Literature. <b>2017</b> , 24, 247-257	26
922	Persistent organic pollutants (POPs) in human follicular fluid and in vitro fertilization outcomes, a pilot study. <b>2017</b> , 67, 165-173	28
921	The Ovarian Follicle of Cows as a Model for Human. <b>2017</b> , 127-144	8
920	The association of different auto-antibodies against ovarian tissues and gonadotropins and poor ovarian response in intracytoplasmic sperm injection cycles. <b>2017</b> , 20, 126-131	1

919	Proteomic analysis of human follicular fluid in poor ovarian responders during in vitro fertilization. <b>2017</b> , 17, 1600333	10
918	The role of ovarian reserve markers in prediction of clinical pregnancy. <b>2017</b> , 37, 492-497	6
917	Mild versus conventional antagonist ovarian stimulation protocols in expected normal responders undergoing IVF/ICSI: a case-control study. <b>2017</b> , 33, 553-556	4
916	The high responder: a review of pathophysiology and outcomes during IVF treatment. <b>2017</b> , 20, 155-167	11
915	Methods of controlled ovarian stimulation for embryo/oocyte cryopreservation in breast cancer patients. <b>2017</b> , 2, 47-59	8
914	Fertility Preservation and Restoration for Patients with Complex Medical Conditions. <b>2017</b> ,	1
913	Clinical utility of newly developed highly purified human menopausal gonadotrophins: a randomized controlled trial. <b>2017</b> , 34, 499-505	3
912	[Poor responders: How could we improve our results?]. <b>2017</b> , 45, 95-103	4
911	Growth hormone in IVF cycles: any hope?. <b>2017</b> , 29, 119-125	26
910	Age is a major prognosticator in extremely low oocyte retrieval cycles. <b>2017</b> , 56, 175-180	5
909	The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: A systematic review and meta-analysis. <b>2017</b> , 96, e6443	55
908	Association between peak estradiol levels and ovarian torsion among symptomatic patients receiving gonadotropin treatment. <b>2017</b> , 34, 627-631	6
907	Comparison of the morphokinetic parameters of embryos according to ovarian reserve in IVF cycles. <b>2017</b> , 33, 733-736	7
906	Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. <i>Human Reproduction</i> , <b>2017</b> , 32, 544-555	5-7 35
905	Natural Cycle IVF: Summary of the Current Literature. <b>2017</b> , 95-104	
904	Development of In Vitro Maturation for Human Oocytes. <b>2017</b> ,	2
903	[Ovarian hyperstimulation syndrome after stimulation with highly purified hMGfor in vitro fertilization: Observational study SHOview]. <b>2017</b> , 45, 283-290	0
902	Management of ovarian stimulation for IVF: narrative review of evidence provided for World Health Organization guidance. <b>2017</b> , 35, 3-16	16

8901	Serum luteinizing hormone level on the third day after ovarian stimulation in GnRH agonist short protocol is predictive of outcome in poor responders but not in normal responders. <b>2017</b> , 33, 57-61		1
8900	Ovarian response to controlled ovarian hyperstimulation: what does serum FSH say?. <i>Human Reproduction</i> , <b>2017</b> , 32, 1701-1709	5-7	11
899	Which Women Are Suitable for Natural and Modified Natural Cycle IVF?. <b>2017</b> , 147-155		
898	Corifollitropin alfa compared with follitropin beta in GnRH-antagonist ovarian stimulation protocols in an unselected population undergoing IVF/ICSI. <b>2017</b> , 33, 968-971		2
897	[Systematic proposal of fertility preservation by mature oocyte cryopreservation for recurrent benign ovarian tumors]. <b>2017</b> , 45, 359-365		3
896	Factors associated with a poor prognosis for the IVF-ICSI live birth rate in women with rAFS stage III and IV endometriosis. <b>2017</b> , 34, 921-928		3
895	Cumulative live birth and surplus embryo incidence after frozen-thaw cycles in PCOS: how many oocytes do we need?. <b>2017</b> , 34, 1153-1159		6
894	Telemonitoring in IVF/ICSI. <b>2017</b> , 29, 160-167		6
893	Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles. <b>2017</b> , 5, CD005070		39
892	Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. <i>Human Reproduction</i> , <b>2017</b> , 32, 1537-1538	5-7	44
891	Live birth rate following oral antibiotic treatment for chronic endometritis in infertile women with repeated implantation failure. <b>2017</b> , 78, e12719		79
890	Comparaci3n entre el uso de corifolitropina alfa frente a gonadotropinas convencionales en pacientes con diagn3stico de baja respuesta ov3rica seg3n los criterios de Bolonia. <b>2017</b> , 4, 11-16		
889	Niveles de hormona antimulleriana en suero y l3quidos foliculares como marcadores predictivos de respuesta ov3rica en tratamientos de reproducci3n asistida. <b>2017</b> , 4, 22-31		
888	Premature Ovarian Insufficiency. <b>2017</b> , 197-215		
887	Live birth rates in various subgroups of poor ovarian responders fulfilling the Bologna criteria. <b>2017</b> , 34, 639-644		42
886	Follicular output rate can predict clinical pregnancy in women with unexplained infertility undergoing IVF/ICSI: a prospective cohort study. <b>2017</b> , 34, 598-604		18
885	A post-publication analysis of the idealized upper reference value of 2.5 mIU/L for TSH: Time to support the thyroid axis with magnesium and iron especially in the setting of reproduction medicine. <b>2017</b> , 7, 115-119		5
884	Dehydroepiandrosterone (DHEA) supplementation and IVF outcome in poor responders. <b>2017</b> , 20, 80-87		8

883	Implantation rates subsequent to the transfer of embryos produced at different phases during double stimulation of poor ovarian responders. <b>2017</b> , 29, 1178-1183	8
882	Effect of mid-follicular phase recombinant LH versus urinary HCG supplementation in poor ovarian responders undergoing IVF - a prospective double-blinded randomized study. <b>2017</b> , 34, 258-266	16
881	Live birth rates are satisfactory following multiple IVF treatment cycles in poor prognosis patients. <b>2017</b> , 17, 34-41	3
880	Dual trigger of final oocyte maturation in poor ovarian responders undergoing IVF/ICSI cycles. <b>2017</b> , 35, 701-707	18
879	[How to deal with the different serum AMH kits in France in 2017?]. <b>2017</b> , 45, 558-565	5
878	Menopause. <b>2017</b> ,	2
877	Heyan Kuntai capsule versus dehydroepiandrosterone in treating Chinese patients with infertility caused by diminished ovarian reserve: a multicenter, randomized controlled trial. <b>2017</b> , 37, 530-537	2
876	Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis. <b>2017</b> , 7, e018107	29
875	Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial. <i>Human Reproduction</i> , <b>2017</b> , 32, 2225-2233 <sup>5:7</sup>	26
874	Idiopathic Low Ovarian Reserve Is Associated with More Frequent Positive Thyroid Peroxidase Antibodies. <b>2017</b> , 27, 1194-1200	27
873	Efficacy of Dehydroepiandrosterone (DHEA) to overcome the effect of ovarian ageing (DITTO): A proof of principle double blinded randomized placebo controlled trial. <b>2017</b> , 218, 39-48	15
872	Low oocyte yield during IVF treatment and the risk of a trisomic pregnancy. <b>2017</b> , 35, 685-692	3
871	miR-15a-5p levels correlate with poor ovarian response in human follicular fluid. <b>2017</b> , 154, 483-496	10
870	Effect of follicular flushing on reproductive outcomes in patients with poor ovarian response undergoing assisted reproductive technology. <b>2017</b> , 34, 1353-1357	10
869	Outcome of ICSI with motile testicular spermatozoa obtained through microscopically assisted testicular sperm extraction in relation to the ovarian response. <b>2017</b> , 46, 405-410	1
868	Ovarian response prediction in controlled ovarian stimulation for IVF using anti-Müllerian hormone in Chinese women: A retrospective cohort study. <b>2017</b> , 96, e6495	11
867	Colorectal endometriosis-associated infertility: should surgery precede ART?. <b>2017</b> , 108, 525-531.e4	37
866	Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing IVF/ICSI. <b>2017</b> ,	2

865	The Effect of Instant Urinary Catheterization on Pregnancy Outcomes after Intracytoplasmic Sperm Injection and Embryo Transfer. <b>2017</b> , 82, 563-568		
864	Tiaogeng Yijing decoction improves the pregnancy outcomes of patients with poor ovarian response undergoing fertilization-embryo transfer. <b>2017</b> , 14, 3935-3941		2
863	Primary Ovarian Insufficiency. <b>2017</b> , 23-66		1
862	Luteal-phase protocol in poor ovarian response: a comparative study with an antagonist protocol. <b>2017</b> , 45, 1731-1738		8
861	Follicular sensitivity index (FSI): a novel tool to predict clinical pregnancy rate in IVF/ICSI cycles. <b>2017</b> , 34, 1317-1324		9
860	Freeze-all cycle for all normal responders?. <b>2017</b> , 34, 179-185		26
859	Optimal embryo transfer strategy in poor response may include freeze-all. <b>2017</b> , 34, 79-87		21
858	Protection of cumulus cells following dehydroepiandrosterone supplementation. <b>2017</b> , 33, 100-104		11
857	Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: The predicted poor responder. <i>Human Reproduction</i> , <b>2017</b> , 32, 2496-2505	5:7	69
856	Growth hormone co-treatment in IVF/ICSI cycles in poor responders. <b>2017</b> , 33, 15-17		19
855	Age-specific serum anti-Müllerian hormone concentration in Japanese women and its usefulness as a predictor of the ovarian response. <b>2017</b> , 16, 364-373		10
854	The Application of Dehydroepiandrosterone on Improving Mitochondrial Function and Reducing Apoptosis of Cumulus Cells in Poor Ovarian Responders. <b>2017</b> , 14, 585-594		17
853	Successful Pregnancy after Treatment with Chinese Herbal Medicine in a 43-Year-Old Woman with Diminished Ovarian Reserve and Multiple Uterus Fibrosis: A Case Report. <b>2017</b> , 4,		5
852	Anti-Müllerian hormone dynamics during GnRH-antagonist short protocol for IVF/ICSI in women with varying ovarian reserve levels. <b>2017</b> , 69, 128-134		2
851	fertilization outcome in women with diminished ovarian reserve. <b>2017</b> , 60, 46-52		12
850	Fragile X-Associated Diminished Ovarian Reserve and Primary Ovarian Insufficiency from Molecular Mechanisms to Clinical Manifestations. <b>2017</b> , 10, 290		32
849	Outcomes and Recommendations of an Indian Expert Panel for Improved Practice in Controlled Ovarian Stimulation for Assisted Reproductive Technology. <b>2017</b> , 2017, 9451235		5
848	Inositol and In Vitro Fertilization with Embryo Transfer. <b>2017</b> , 2017, 5469409		14

847	Anti-Müllerian hormone levels to predict oocyte maturity and embryo quality during controlled ovarian hyperstimulation. <b>2017</b> , 69, 225-232	5
846	Comparisons of GnRH antagonist protocol versus GnRH agonist long protocol in patients with normal ovarian reserve: A systematic review and meta-analysis. <b>2017</b> , 12, e0175985	35
845	Menstrual cycle characteristics of young females with occult primary ovarian insufficiency at initial diagnosis and one-year follow-up with serum amh level and antral follicle count. <b>2017</b> , 12, e0188334	8
844	Fertility with early reduction of ovarian reserve: the last straw that breaks the Camel's back. <b>2017</b> , 3, 15	29
843	How to personalize ovarian stimulation in clinical practice. <b>2017</b> , 18, 148-153	9
842	Mild Conventional Ovarian Stimulation for Poor Responders Undergoing IVF/ICSI. <b>2017</b> , 31, 231-237	18
841	fertilization outcomes in women with surgery induced diminished ovarian reserve after endometrioma operation: Comparison with diminished ovarian reserve without ovarian surgery. <b>2017</b> , 60, 63-68	20
840	Mid-luteal estradiol levels of poor/good responders and intracytoplasmic sperm injection. <b>2017</b> , 33, 182-186	1
839	Can ovarian double-stimulation in the same menstrual cycle improve IVF outcomes?. <b>2017</b> , 21, 217-221	19
838	Administration of low-molecular-weight heparin in patients with two or more unsuccessful IVF/ICSI cycles: a multicenter cohort study. <b>2018</b> , 34, 747-751	6
837	Freeze-all embryo strategy in poor ovarian responders undergoing ovarian stimulation for in vitro fertilization. <b>2018</b> , 34, 680-683	9
836	The use of anti-Müllerian hormone for controlled ovarian stimulation in assisted reproductive technology, fertility assessment and -counseling. <b>2018</b> , 97, 1105-1113	11
835	Influence of follicular fluid and cumulus cells on oocyte quality: clinical implications. <b>2018</b> , 35, 735-751	79
834	Outcomes of poor responders following growth hormone co-treatment with IVF/ICSI mild stimulation protocol: a retrospective cohort study. <b>2018</b> , 297, 1317-1321	15
833	Low oxygen environment facilitates embryo availability for older ovarian responders (PORs). <b>2018</b> , 34, 905-908	1
832	Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial. <b>2018</b> , 16, 29	80
831	What is new in the management of poor ovarian response in IVF?. <b>2018</b> , 30, 155-162	49
830	The end for individualized dosing in IVF ovarian stimulation? Reply to letters-to-the-editor regarding the OPTIMIST papers. <i>Human Reproduction</i> , <b>2018</b> , 33, 984-988	5-7 5



829	Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review. <b>2018</b> , 109, 644-664	59
828	[In vitro fertilization versus conversion to intrauterine insemination in patients with poor response to controlled ovarian hyperstimulation]. <b>2018</b> , 46, 118-123	3
827	Poor ovarian response as a predictor for live birth in older women undergoing IVF. <b>2018</b> , 36, 435-441	12
826	Antral Follicle Diameter Variance Within Each Ovary May Be A Predictor For Poor Response In Cases With Normal Ovarian Reserve. <b>2018</b> , 126, 521-527	2
825	Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). <b>2018</b> , 2, CD012693	48
824	Comparison of clinical outcomes among dual ovarian stimulation, mild stimulation and luteal phase stimulation protocols in women with poor ovarian response. <b>2018</b> , 34, 694-697	19
823	Pharmacogenetics of G-protein-coupled receptors variants: FSH receptor and infertility treatment. <b>2018</b> , 32, 189-200	14
822	Human Papillomavirus Prophylactic Vaccination improves reproductive outcome in infertile patients with HPV semen infection: a retrospective study. <b>2018</b> , 8, 912	29
821	An ART score to note objectively the quality of an ART procedure. <b>2018</b> , 221, 52-57	3
820	No. 356-Egg Freezing for Age-Related Fertility Decline. <b>2018</b> , 40, 356-368	16
819	N 356-Congélation d'ovules pour pallier le déclin de la fertilité féminine. <b>2018</b> , 40, 369-383	
818	Follicular flushing in patients with poor ovarian response: a systematic review and meta-analysis. <b>2018</b> , 36, 408-415	13
817	Does freeze-all policy affect IVF outcome in poor ovarian responders?. <b>2018</b> , 52, 530-534	17
816	Lower follicular fluid vitamin D concentration is related to a higher number of large ovarian follicles. <b>2018</b> , 36, 277-284	7
815	Increased proportion of mature oocytes with sustained-release growth hormone treatment in poor responders: a prospective randomized controlled study. <b>2018</b> , 297, 791-796	16
814	A comparison of treatment results of the different treatment protocols in patients with poor ovarian response. <b>2018</b> , 34, 524-527	3
813	Predictive value of antral follicle count and serum anti-Müllerian hormone: Which is better for live birth prediction in patients aged over 40 with their first IVF treatment?. <b>2018</b> , 221, 151-155	9
812	Low dosing of gonadotropins in in vitro fertilization cycles for women with poor ovarian reserve: systematic review and meta-analysis. <b>2018</b> , 109, 289-301	19

811	Broad support for regulating the clinical implementation of future reproductive techniques. <i>Human Reproduction</i> , <b>2018</b> , 33, 39-46	5-7	5
810	Bologna criteria: clinically or academically relevant?. <b>2018</b> , 109, 59-60		4
809	The dilemma of aneuploidy screening on low responders. <b>2018</b> , 30, 179-184		5
808	ICSI cycles in women over 40 years: analysis of 3 different ovarian stimulation protocols. <b>2018</b> , 23, 319-323		
807	Individualized controlled ovarian stimulation in expected poor-responders: an update. <b>2018</b> , 16, 20		49
806	Urinary phthalate metabolites in relation to serum anti-Müllerian hormone and inhibin B levels among women from a fertility center: a retrospective analysis. <b>2018</b> , 15, 33		12
805	Anti-Müllerian hormone levels and spontaneous pregnancy in women undergoing surgery for benign ovarian cysts. <b>2018</b> , 34, 909-912		2
804	Poor definition of poor-ovarian response results in misleading clinical recommendations. <i>Human Reproduction</i> , <b>2018</b> , 33, 979-980	5-7	9
803	Usefulness of individualized FSH, LH and GH dosing in ovarian stimulation of women with low ovarian reserve. <i>Human Reproduction</i> , <b>2018</b> , 33, 981-982	5-7	4
802	Role of ICSI in Non-male Factor Cycles as the Number of Oocytes Retrieved Decreases from Four to One. <b>2018</b> , 38, 131-136		5
801	[Deeply infiltrating endometriosis and infertility: CNGOF-HAS Endometriosis Guidelines]. <b>2018</b> , 46, 357-367		8
800	Luteal-phase ovarian stimulation increases the number of mature oocytes in older women with severe diminished ovarian reserve. <b>2018</b> , 64, 216-219		15
799	Characterization of a suboptimal IVF population and clinical outcome after two IVF cycles. <b>2018</b> , 34, 125-128		4
798	Finding a place for corifollitropin within the PIVET FSH dosing algorithms. <b>2018</b> , 36, 47-58		8
797	Counting ovarian antral follicles by ultrasound: a practical guide. <b>2018</b> , 51, 10-20		47
796	Insights from clinical experience in treating IVF poor responders. <b>2018</b> , 36, 12-19		23
795	Reproductive ovarian testing and the alphabet soup of diagnoses: DOR, POI, POF, POR, and FOR. <b>2018</b> , 35, 17-23		48
794	Donor sperm insemination after failed intra-couple intracytoplasmic sperm injection. <b>2018</b> , 64, 130-137		3

793	Administration of prednisolone and low molecular weight heparin in patients with repeated implantation failures: a cohort study. <b>2018</b> , 34, 136-139	16
792	The impact of unilateral oophorectomy on ovarian reserve in assisted reproduction: a systematic review and meta-analysis. <b>2018</b> , 125, 26-35	11
791	Utilization of the Bologna criteria: a promise unfulfilled? A review of published and unpublished/ongoing trials. <b>2018</b> , 109, 104-109.e2	13
790	Melatonin concentration in follicular fluid is correlated with antral follicle count (AFC) and in vitro fertilization (IVF) outcomes in women undergoing assisted reproductive technology (ART) procedures. <b>2018</b> , 34, 446-450	23
789	Does using testicular sperm retrieval rather than ejaculated spermatozoa improve reproductive outcomes in couples with previous ART failure and poor ovarian response? A case-controlled study. <b>2018</b> , 6, 142-145	1
788	Urinary concentrations of biomarkers of phthalates and phthalate alternatives and IVF outcomes. <b>2018</b> , 111, 23-31	53
787	The "vanishing follicle" in women with low number of developing follicles during assisted reproduction. <b>2018</b> , 220, 6-11	
786	Anti-Müllerian hormone in type 2 and gestational diabetes during the second half of pregnancy: relationship with sexual steroid levels and metabolic parameters. <b>2018</b> , 34, 120-124	6
785	Dehydroepiandrosterone supplementation in women undergoing assisted reproductive technology with poor ovarian response. A prospective case-control study. <b>2018</b> , 46, 143-149	8
784	Variabilität des Anti-Müller-Hormon-Werts nach gonadotoxischer Therapie. <b>2018</b> , 16, 61-63	
783	ANDRO-IVF: a novel protocol for poor responders to IVF controlled ovarian stimulation. <b>2018</b> , 22, 52-55	3
782	Absence of a correlation between intra-follicular androgen and AMH levels and the oocyte count in poor responder patients undergoing in vitro fertilization. <b>2018</b> , 1073, 032050	
781	Delayed Start Protocol with Gonadotropin-releasing Hormone Antagonist in Poor Responders Undergoing In Vitro Fertilization: A Randomized, Double-blinded, Clinical Trial. <b>2018</b> , 33, 506-511	2
780	Premature ovarian insufficiency identified as a kidney deficiency and liver constraint pattern treated by Professor Zhiqiang Guo: A retrospective analysis. <b>2018</b> , 5, 344-349	
779	Natural cycle versus hormone replacement therapy cycle in frozen-thawed embryo transfer. <b>2018</b> , 39, 1102-1108	10
778	The effect of the pooling method on the live birth rate in poor ovarian responders according to the Bologna criteria. <b>2018</b> , 15, 39-45	2
777	Effects of Dehydroepiandrosterone (DHEA) Supplementation to Improve Ovarian Response and IVF Outcomes on Women with Poor Ovarian Response. <b>2018</b> ,	
776	Use of Clomiphene Citrate in minimal stimulation in vitro fertilization negatively impacts endometrial thickness: an argument for a freeze-all approach. <b>2018</b> , 22, 355-362	6

775	Correlation between androgen levels in follicular fluid and granulosa cell FSHR expression in poor responder women. <b>2018</b> , 1073, 032054	
774	Effect of Dandelion Extracts on the Proliferation of Ovarian Granulosa Cells and Expression of Hormone Receptors. <b>2018</b> , 131, 1694-1701	0
773	GnRH agonist long protocol versus GnRH antagonist protocol for various aged patients with diminished ovarian reserve: A retrospective study. <b>2018</b> , 13, e0207081	14
772	Assessment of the development of assisted reproductive technology in Liaoning province of China, from 2012 to 2016. <b>2018</b> , 18, 873	8
771	Extracellular microRNAs profile in human follicular fluid and IVF outcomes. <b>2018</b> , 8, 17036	40
770	Endogenous Ovarian Angiogenesis in Polycystic Ovary Syndrome-Like Rats Induced by Low-Frequency Electro-Acupuncture: The CLARITY Three-Dimensional Approach. <b>2018</b> , 19,	13
769	Anti-müllerian Hormone During Natural Cycle Presents Significant Intra and Intercycle Variations When Measured With Fully Automated Assay. <b>2018</b> , 9, 686	13
768	Transcriptional landscape of mouse-aged ovaries reveals a unique set of non-coding RNAs associated with physiological and environmental ovarian dysfunctions. <b>2018</b> , 4, 112	16
767	Gene expression of follicle-stimulating hormone receptors in granulosa cells in poor ovarian responders. <b>2018</b> , 1073, 032068	
766	Luteal phase ovarian stimulation for poor ovarian responders. <b>2018</b> , 22, 193-198	14
765	The Consultation with the Poor Responder. 14-18	
764	Factors affecting the live-birth rate in women with diminished ovarian reserve undergoing IVF-ET. <b>2018</b> , 298, 1017-1027	13
763	In vitro maturation (IVM) of oocytes in patients with resistant ovary syndrome and in patients with repeated deficient oocyte maturation. <b>2018</b> , 35, 2161-2171	19
762	Infertility: a marker of future health risk in women?. <b>2018</b> , 110, 783-789	9
761	Endometrial injury for patients with endometriosis and polycystic ovary syndrome undergoing medically assisted reproduction: current data and a protocol. <b>2018</b> , 35,	2
760	Understanding Ovarian Hypo-Response to Exogenous Gonadotropin in Ovarian Stimulation and Its New Proposed Marker-The Follicle-To-Oocyte (FOI) Index. <b>2018</b> , 9, 589	56
759	Ovarian stimulation with corifollitropin alfa followed by hp-hMG compared to hp-hMG in patients at risk of poor ovarian response undergoing ICSI: A randomized controlled trial. <b>2018</b> , 231, 192-197	3
758	ConFIRM trial - conversion of in vitro fertilization cycles to intrauterine inseminations in patients with a poor ovarian response to stimulation: a protocol for a multicentric, prospective randomized trial. <b>2018</b> , 19, 565	2

757	Dehydroepiandrosterone (DHEA) supplementation improves in vitro fertilization outcomes of poor ovarian responders, especially in women with low serum concentration of DHEA-S: a retrospective cohort study. <b>2018</b> , 16, 90		24
756	Low Gonadotropin Dosage Reduces Aneuploidy in Human Preimplantation Embryos: First Clinical Study in a UAE Population. <b>2018</b> , 22, 630-634		3
755	A randomized, open phase IV exploratory clinical trial to evaluate the efficacy and safety of acupuncture on the outcome of induction of ovulation in women with poor ovarian response: A study protocol for a randomized controlled trial. <b>2018</b> , 97, e11813		4
754	Delayed childbearing and female ageing impair assisted reproductive technology outcome in survivors of male haematological cancers. <b>2018</b> , 35, 2049-2056		2
753	Impact of polar body biopsy on embryo morphokinetics-back to the roots in preimplantation genetic testing?. <b>2018</b> , 35, 1521-1528		2
752	The influence of body mass index on pregnancy outcome following single-embryo transfer. <b>2018</b> , 35, 1295-1300		11
751	Intracytoplasmic sperm injection for male infertility and consequences for offspring. <b>2018</b> , 15, 535-562		69
750	Autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders. <b>2018</b> , 110, 496-505.e1		44
749	The addition of growth hormone adjuvant therapy to the long down regulation protocol in poor responders undergoing in vitro fertilization: Randomized control trial. <b>2018</b> , 228, 161-165		26
748	Preimplantation genetic testing for aneuploidy by microarray analysis of polar bodies in advanced maternal age: a randomized clinical trial. <i>Human Reproduction</i> , <b>2018</b> , 33, 1767-1776	5-7	64
747	Is the ovarian reserve influenced by vitamin D deficiency and the dress code in an infertile Iranian population?. <b>2018</b> , 11, 62		12
746	Forty years of IVF. <b>2018</b> , 110, 185-324.e5		108
745	FMR1 expression in human granulosa cells increases with exon 1 CGG repeat length depending on ovarian reserve. <b>2018</b> , 16, 65		12
744	Monitoring COS and HRT Cycles. <b>2018</b> , 20-24		
743	Evaluation and ART of the Low Ovarian Responder Patient. <b>2018</b> , 299-303		
742	DHEA Supplementation Confers No Additional Benefit to that of Growth Hormone on Pregnancy and Live Birth Rates in IVF Patients Categorized as Poor Prognosis. <b>2018</b> , 9, 14		8
741	Double Stimulation in the Same Ovarian Cycle (DuoStim) to Maximize the Number of Oocytes Retrieved From Poor Prognosis Patients: A Multicenter Experience and SWOT Analysis. <b>2018</b> , 9, 317		57
740	Micro-RNAs involved in cellular proliferation have altered expression profiles in granulosa of young women with diminished ovarian reserve. <b>2018</b> , 35, 1777-1786		21

739	Response: Commentary: Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the "Personalized" Medicine Era: A Meta-analysis. <b>2018</b> , 9, 113	4
738	Anti-müllerian hormone levels are associated with live birth rates in ART, but the predictive ability of anti-müllerian hormone is modest. <b>2018</b> , 225, 199-204	18
737	Predicting live birth for poor ovarian responders: the PROsPeR concept. <b>2018</b> , 37, 43-52	7
736	Cytoplasmic abnormalities of mature oocytes have a significant effect on fertilization in Bologna poor responders. <b>2018</b> , 48, 750-758	1
735	Indication-oriented Ovulation Induction in Assisted Reproduction. <b>2018</b> , 14,	
734	Preimplantation genetic diagnosis versus prenatal diagnosis-decision-making among pregnant FMR1 premutation carriers. <b>2018</b> , 35, 2071-2075	7
733	Conventional versus minimal ovarian stimulation: an intra-patient comparison of ovarian response in poor-responder women according to Bologna Criteria. <b>2018</b> , 37, 434-441	9
732	Rotterdam criteria, the end. <b>2018</b> , 21, 59-60	1
731	Efficacy of luteal estrogen administration and an early follicular Gonadotropin-releasing hormone antagonist priming protocol in poor responders undergoing fertilization. <b>2018</b> , 61, 102-110	6
730	Endometrial thickness of less than 7.5 mm is associated with obstetric complications in fresh IVF cycles: a retrospective cohort study. <b>2018</b> , 37, 341-348	26
729	The impact of endometrial thickness (EMT) on the day of human chorionic gonadotropin (hCG) administration on pregnancy outcomes: a 5-year retrospective cohort analysis in Malaysia. <b>2018</b> , 4, 5	11
728	Early stop of progesterone supplementation after confirmation of pregnancy in IVF/ICSI fresh embryo transfer cycles of poor responders does not affect pregnancy outcome. <b>2018</b> , 13, e0201824	7
727	Defining Low Prognosis Patients Undergoing Assisted Reproductive Technology: POSEIDON Criteria-The Why. <b>2018</b> , 9, 461	64
726	What to do when good-quality embryos repeatedly fail to implant. <b>2018</b> , 53, 48-59	16
725	Unleashing the potential of stem cells to help poor responders. <b>2018</b> , 110, 410-411	1
724	EndoART: A proposed randomized controlled trial on endometriomas in assisted reproductive technologies, comparing the effect of no intervention, surgery, and prolonged GnRH downregulation on pregnancy rates. <b>2018</b> , 10, 158-173	5
723	Endometriosis and ART: A prior history of surgery for OMA is associated with a poor ovarian response to hyperstimulation. <b>2018</b> , 13, e0202399	13
722	A pharmacogenetic approach to improve low ovarian response: The role of CAG repeats length in the androgen receptor gene. <b>2018</b> , 227, 41-45	2

721	Luteal Phase Ovarian Stimulation May Improve Oocyte Retrieval and Oocyte Quality in Poor Ovarian Responders Undergoing In Vitro Fertilization: Preliminary Results from a Single-Center Prospective Pilot Study. <b>2018</b> , 35, 847-856	21
720	Conversion to IUI versus continuance with IVF in low responder patients: A systematic review. <b>2018</b> , 227, 35-40	5
719	Cumulative live birth rates in more than 3,000 patients with poor ovarian response: a 15-year survey of final in vitro fertilization outcome. <b>2018</b> , 109, 1051-1059	28
718	Personalized ovarian stimulation for assisted reproductive technology: study design considerations to move from hype to added value for patients. <b>2018</b> , 109, 968-979	23
717	Anti-Müllerian Hormone (AMH) in Adults. <b>2019</b> , 556-566	
716	Effect of Body Weight on Metabolic Hormones and Fatty Acid Metabolism in Follicular Fluid of Women Undergoing In Vitro Fertilization: A Pilot Study. <b>2019</b> , 26, 404-411	11
715	Assisted Reproduction. <b>2019</b> , 779-822.e16	2
714	Pelvic Imaging in Reproductive Endocrinology. <b>2019</b> , 916-961.e5	
713	A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients. <b>2019</b> , 84, 99-106	42
712	Androgens Profile in Blood Serum and Follicular Fluid of Women With Poor Ovarian Response During Controlled Ovarian Stimulation Reveals Differences Amongst POSEIDON Stratification Groups: A Pilot Study. <b>2019</b> , 10, 458	4
711	The impact of different etiologies of diminished ovarian reserve on pregnancy outcome in IVF-ET cycles. <b>2019</b> , 49, 1138-1144	2
710	GnRH $\alpha$ for Ovarian Protection and the Association between AMH and Ovarian Function during Adjuvant Chemotherapy for Breast Cancer. <b>2019</b> , 10, 4278-4285	11
709	Investigating the effect of lifestyle risk factors upon number of aspirated and mature oocytes in in vitro fertilization cycles: Interaction with antral follicle count. <b>2019</b> , 14, e0221015	6
708	Use of Growth Hormone in the IVF Treatment of Women With Poor Ovarian Reserve. <b>2019</b> , 10, 500	19
707	Decision points for individualized hormonal stimulation with recombinant gonadotropins for treatment of women with infertility. <b>2019</b> , 35, 1027-1036	8
706	ICSI does not offer any benefit over conventional IVF across different ovarian response categories in non-male factor infertility: a European multicenter analysis. <b>2019</b> , 36, 2067-2076	13
705	Modified ovarian response prediction index: a novel index for ovarian response prediction in GnRH agonist cycles. <b>2019</b> , 8, 2575	0
704	Is there an association between oocyte number and embryo quality? A systematic review and meta-analysis. <b>2019</b> , 39, 751-763	18

703	Cumulative Live Birth Rates of Good and Low Prognosis Patients According to POSEIDON Criteria: A Single Center Analysis of 18,455 Treatment Cycles. <b>2019</b> , 10, 409	24
702	Discordance between antral follicle counts and anti-Müllerian hormone levels in women undergoing in vitro fertilization. <b>2019</b> , 17, 51	11
701	Oncofertility conundrum: discrepancy between anti-Müllerian hormone and mature oocyte yield in a peripubertal girl with Hodgkin lymphoma. <b>2019</b> , 36, 1753-1756	1
700	Common Stimulation Regimens in Assisted Reproductive Technology. <b>2019</b> , 131-137	
699	Cumulative Live Birth Rates in Low Prognosis Patients According to the POSEIDON Criteria: An Analysis of 26,697 Cycles of Fertilization/Intracytoplasmic Sperm Injection. <b>2019</b> , 10, 642	24
698	Biopsying, fragmentation and autotransplantation of fresh ovarian cortical tissue in infertile women with diminished ovarian reserve. <i>Human Reproduction</i> , <b>2019</b> , 34, 1924-1936	5-7 22
697	Poor ovarian response is associated with serum vitamin D levels and pro-inflammatory immune responses in women undergoing in-vitro fertilization. <b>2019</b> , 136, 102617	3
696	Progestin-primed ovarian stimulation vs mild stimulation in women with advanced age above 40: a retrospective cohort study. <b>2019</b> , 17, 91	3
695	Ovarian stimulation and assisted reproductive technology outcomes in women transplanted with cryopreserved ovarian tissue: a systematic review. <b>2019</b> , 112, 908-921	21
694	Are early follicular phase serum progrenulin levels predictive of the response to ovarian stimulation in IVF cycles?. <b>2019</b> , 1-6	2
693	Management Strategies for POSEIDON's Group 1. <b>2019</b> , 10, 679	11
692	Is There a Need to Alter the Timing of Anti-Müllerian Hormone Measurement During the Menstrual Cycle?. <b>2019</b> , 79, 731-737	5
691	FSH Requirements for Follicle Growth During Controlled Ovarian Stimulation. <b>2019</b> , 10, 579	6
690	Serum Concentrations of Oocyte-Secreted Factors BMP15 and GDF9 During IVF and in Women With Reproductive Pathologies. <b>2019</b> , 160, 2298-2313	8
689	Predicting the likelihood of a live birth for women with endometriosis-related infertility. <b>2019</b> , 242, 56-62	7
688	Dual stimulation using corifollitropin alfa in 54 Bologna criteria poor ovarian responders - a case series. <b>2019</b> , 38, 677-682	22
687	Female subfertility. <b>2019</b> , 5, 7	34
686	Novel approaches for diagnosis and management of low prognosis patients in assisted reproductive technology: the POSEIDON concept. <b>2019</b> , 61, 24-29	31



685	Human Defensin 1 in follicular fluid and semen: impact on fertility. <b>2019</b> , 36, 787-797	8
684	A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany. <b>2019</b> , 11, 319-331	3
683	Cumulative live birth rates in low-prognosis women. <i>Human Reproduction</i> , <b>2019</b> , 34, 1030-1041	5:7 41
682	An artificial neural network for the prediction of assisted reproduction outcome. <b>2019</b> , 36, 1441-1448	21
681	Comparison of GnRH agonist versus luteal estradiol GnRH antagonist protocol using transdermal testosterone in poor responders. <b>2019</b> , 23, 130-136	4
680	Body mass index in relation to extracellular vesicle-linked microRNAs in human follicular fluid. <b>2019</b> , 112, 387-396.e3	8
679	Anti-müllerian Hormone for the Prediction of Ovarian Response in Progesterin-Primed Ovarian Stimulation Protocol for IVF. <b>2019</b> , 10, 325	7
678	The relationship between FSH receptor polymorphism status and IVF cycle outcome: a retrospective observational study. <b>2019</b> , 39, 231-240	6
677	Do young women with unexplained infertility show manifestations of decreased ovarian reserve?. <b>2019</b> , 36, 1143-1152	6
676	Modified natural cycle IVF versus conventional stimulation in advanced-age Bologna poor responders. <b>2019</b> , 39, 698-703	14
675	Ovarian Reserve Markers to Identify Poor Responders in the Context of Poseidon Classification. <b>2019</b> , 10, 281	35
674	Serum and follicular fluid Stem Cell Factor assay in IVF poor responder and normal responder patients: a predictive biomarker of oocyte retrieval. <b>2019</b> , 300, 447-454	0
673	The incidence of unexpected poor ovarian response in Chinese young women. <b>2019</b> , 98, e14379	3
672	Is corifollitropin alfa effective in controlled ovarian stimulation among all poor ovarian responders? A retrospective comparative study. <b>2019</b> , 35, 894-898	3
671	An Observational Retrospective Cohort Trial on 4,828 IVF Cycles Evaluating Different Low Prognosis Patients Following the POSEIDON Criteria. <b>2019</b> , 10, 282	16
670	Understanding Follicular Output Rate (FORT) and its Implications for POSEIDON Criteria. <b>2019</b> , 10, 246	14
669	Association of Mutations and Anti-müllerian Hormone Level in Young Breast Cancer Patients. <b>2019</b> , 10, 235	21
668	Do poor-responder patients undergoing IVF benefit from splitting and increasing the daily gonadotropin dose?. <b>2019</b> , 35, 890-893	2

667	The relative importance of genetic parenthood. <b>2019</b> , 39, 103-110	6
666	Evaluation of the Elecsys anti-Müllerian hormone assay for the prediction of hyper-response to controlled ovarian stimulation with a gonadotrophin-releasing hormone antagonist protocol. <b>2019</b> , 236, 133-138	2
665	The role of progesterone/estradiol ratio in exploring the mechanism of late follicular progesterone elevation in low ovarian reserve women. <b>2019</b> , 125, 126-128	3
664	Does double trigger (GnRH-agonist + hCG) improve outcome in poor responders undergoing IVF-ET cycle? A pilot study. <b>2019</b> , 35, 628-630	12
663	Evaluation of the Second Follicular Wave Phenomenon in Natural Cycle Assisted Reproduction: A Key Option for Poor Responders through Luteal Phase Oocyte Retrieval. <b>2019</b> , 55,	10
662	Cumulative live birth rate of advanced-age women more than 40 with or without poor ovarian response. <b>2019</b> , 58, 201-205	8
661	Follicular fluid concentrations of phthalate metabolites are associated with altered intrafollicular reproductive hormones in women undergoing in vitro fertilization. <b>2019</b> , 111, 953-961	20
660	Cumulative Live Birth Rates Following Stimulation With Corifollitropin Alfa Compared With hp-hMG in a GnRH Antagonist Protocol in Poor Ovarian Responders. <b>2019</b> , 10, 175	7
659	Comparing early embryo morphokinetics with time-lapse microscopy in patients with low and normal ovarian response to ovarian stimulation. <b>2019</b> , 19, 127-132	7
658	MRAP2 regulates endometrial receptivity and function. <b>2019</b> , 703, 7-12	2
657	Triggering method in assisted reproduction alters the cumulus cell transcriptome. <b>2019</b> , 39, 211-224	4
656	Messenger RNA and protein expression of tumor necrosis factor $\alpha$ and its receptors in human follicular granulosa cells. <b>2019</b> , 234, 20240-20248	0
655	The Use of DHEA to Improve Oocyte Quality. <b>2019</b> , 141-149	
654	The Use of LH Supplements to Improve the Response to Ovarian Stimulation. <b>2019</b> , 167-181	
653	Stimulating the Poor Responder. <b>2019</b> , 368-374	
652	Human growth hormone for poor responders: a randomized placebo-controlled trial provides no evidence for improved live birth rate. <b>2019</b> , 38, 908-915	38
651	Age at menarche and clinical outcomes following medically assisted reproduction (MAR): a cohort study. <b>2019</b> , 35, 448-452	1
650	[Medically Assisted Reproduction in Natural Cycle: Outcome Evaluation of a Reproductive Medicine Department]. <b>2019</b> , 32, 25-29	1

649	Low Dose Growth Hormone Adjuvant Treatment With Ultra-Long Ovarian Stimulation Protocol in Poor Responders Showed Non-inferior Pregnancy Outcome Compared With Normal Responders. <b>2019</b> , 10, 892	4
648	Factors predicting clinical pregnancy rate of in vitro fertilization-embryo transfer (a STROBE-compliant article). <b>2019</b> , 98, e18246	2
647	The Effect of Growth Hormone on the Clinical Outcomes of Poor Ovarian Reserve Patients Undergoing Fertilization/Intracytoplasmic Sperm Injection Treatment: A Retrospective Study Based on POSEIDON Criteria. <b>2019</b> , 10, 775	9
646	Human Ovarian Granulosa Cells Isolated during an IVF Procedure Exhibit Differential Expression of Genes Regulating Cell Division and Mitotic Spindle Formation. <b>2019</b> , 8,	3
645	Dehydroepiandrosterone Supplementation Improves the Outcomes of Fertilization Cycles in Older Patients With Diminished Ovarian Reserve. <b>2019</b> , 10, 800	6
644	The stimulation protocol in poor responder IVF; a minimal or high-dose stimulation? - A meta-analysis. <b>2019</b> , 41,	3
643	Significant Serum Progesterone Variations on the Day of Final Oocyte Maturation in Stimulated IVF Cycles. <b>2019</b> , 10, 806	2
642	The Evolving Concept of Poor-Prognosis for Women Undertaking IVF and the Notion of Growth Hormone as an Adjuvant; A Single-Center Viewpoint. <b>2019</b> , 10, 808	5
641	Treatment potential of bone marrow-derived stem cells in women with diminished ovarian reserves and premature ovarian failure. <b>2019</b> , 31, 156-162	21
640	Infertility Workup for the Women's Health Specialist: ACOG Committee Opinion, Number 781. <b>2019</b> , 133, e377-e384	70
639	Androgen supplementation in assisted reproduction: where are we in 2019?. <b>2019</b> , 31, 188-194	7
638	Progestin-primed ovarian stimulation improves the outcomes of IVF/ICSI cycles in infertile women with diminished ovarian reserve. <b>2019</b> , 82, 845-848	6
637	Progestin vs. Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surges in Poor Responders Undergoing Fertilization Treatment: A Randomized Controlled Trial. <b>2019</b> , 10, 796	20
636	Growth hormone supplementation may improve the pregnancy rate and endometrial receptivity among women aged more than 40 years undergoing in vitro fertilization. <b>2019</b> , 42, 411-416	6
635	Ovaires et fertilit'en 2019 : pr'servation de la fertilit;, r'serve ovarienne, ovaires polykystiques. <b>2019</b> , 29, 99-104	
634	Double mild stimulation and egg collection in the same cycle for management of poor ovarian responders. <b>2019</b> , 48, 329-333	12
633	Cumulative live birth rate prognosis based on the number of aspirated oocytes in previous ART cycles. <i>Human Reproduction</i> , <b>2019</b> , 34, 171-180	5-7 20
632	The effect of serum vitamin D levels in couples on embryo development and clinical outcomes. <b>2019</b> , 38, 699-710	6

631	Bologna criteria are predictive for ovarian response and live birth in subsequent ovarian stimulation cycles. <b>2019</b> , 299, 571-577	7
630	Effect of body mass index on the outcome of IVF cycles among patients with poor ovarian response. <b>2019</b> , 144, 161-166	8
629	Identification of microRNAs in granulosa cells from patients with different levels of ovarian reserve function and the potential regulatory function of miR-23a in granulosa cell apoptosis. <b>2019</b> , 686, 250-260	21
628	Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve. <b>2019</b> , 17, 7	21
627	Prediction of the lower serum anti-Müllerian hormone threshold for ovarian stimulation prior to in-vitro fertilization using the Elecsys <sup>®</sup> AMH assay: a prospective observational study. <b>2019</b> , 17, 11	6
626	Effect of preconceptional DHEA treatment on in vitro fertilization outcome in poor ovarian respond women: study protocol for a randomized controlled trial. <b>2019</b> , 20, 50	3
625	Pituitary suppression protocol among Bologna poor responders undergoing ovarian stimulation using corifollitropin alfa: does it play any role?. <b>2019</b> , 38, 1010-1017	7
624	Anti Müllerian Hormone: More than a biomarker of female reproductive function. <b>2019</b> , 48, 19-24	28
623	Does the empty follicle syndrome occur in cases of low number of maturing follicles in assisted reproduction?. <b>2019</b> , 35, 305-308	2
622	Progestin-primed ovarian stimulation is a feasible method for poor ovarian responders undergoing in IVF/ICSI compared to a GnRH antagonist protocol: A retrospective study. <b>2019</b> , 48, 99-102	13
621	Women with extreme low AMH values could have in vitro fertilization success. <b>2019</b> , 35, 170-173	12
620	Luteal granulosa cells from natural cycles are more capable of maintaining their viability, steroidogenic activity and LH receptor expression than those of stimulated IVF cycles. <i>Human Reproduction</i> , <b>2019</b> , 34, 345-355	5-7 13
619	Endometrial but not Ovarian Response is Associated With Clinical Outcomes and can be Improved by Prolonged Pituitary Downregulation in Patients With Thin and Medium Endometrium. <b>2019</b> , 26, 1409-1416	9
618	Urinary concentrations of phenols and phthalate metabolites reflect extracellular vesicle microRNA expression in follicular fluid. <b>2019</b> , 123, 20-28	23
617	The relationship between anti-Müllerian hormone serum level and body mass index in a large cohort of infertile patients. <b>2019</b> , 63, 157-163	10
616	The Ovarian Factor in Assisted Reproductive Technology. <b>2019</b> , 379-401	2
615	Risk factors for inadequate response to ovarian stimulation in assisted reproduction cycles: systematic review. <b>2019</b> , 36, 19-28	8
614	Six-week pretreatment with growth hormone improves clinical outcomes of poor ovarian responders undergoing in vitro fertilization treatment: A self-controlled clinical study. <b>2019</b> , 45, 376-381	11

613	A pilot study comparing corifollitropin alfa associated with hp-HMG versus high dose rFSH antagonist protocols for ovarian stimulation in poor responders. <b>2020</b> , 23, 93-100		0
612	Diminished Ovarian Reserve and Assisted Reproductive Technologies. <b>2020</b> ,		2
611	Drug-free in-vitro activation of follicles for infertility treatment in poor ovarian response patients with decreased ovarian reserve. <b>2020</b> , 40, 245-253		41
610	Granulosa-Lutein Cell Sirtuin Gene Expression Profiles Differ between Normal Donors and Infertile Women. <b>2019</b> , 21,		6
609	Prediction of metaphase II oocytes according to different levels of serum AMH in poor responders using the antagonist protocol during ICSI: a cohort study. <b>2020</b> , 36, 728-733		2
608	Individualized ovarian stimulation in IVF/ICSI treatment: it is time to stop using high FSH doses in predicted low responders. <i>Human Reproduction</i> , <b>2020</b> , 35, 1954-1963	5-7	13
607	Gonadotropin versus Follicle-Stimulating Hormone for Ovarian Response in Patients Undergoing in vitro Fertilization: A Retrospective Cohort Comparison. <b>2020</b> , 92, 100572		3
606	Luteal phase after conventional stimulation in the same ovarian cycle might improve the management of poor responder patients fulfilling the Bologna criteria: a case series. <b>2020</b> , 113, 121-130		24
605	Does preimplantation genetic testing for aneuploidy really improve IVF outcomes in advanced maternal age patients without compromising cumulative live-birth rate?. <b>2020</b> , 37, 159		3
604	The potential impact of tumor suppressor genes on human gametogenesis: a case-control study. <b>2020</b> , 37, 341-346		0
603	"Delayed start" gonadotropin-releasing hormone antagonist protocol in Bologna poor-responders: A systematic review and meta-analysis of randomized controlled trials. <b>2020</b> , 244, 154-162		5
602	The effect of intra-ovarian androgen priming on ovarian reserve parameters in Bologna poor responders. <b>2020</b> , 40, 223-228		1
601	Female infertility is associated with an altered expression of the neurokinin B/neurokinin B receptor and kisspeptin/kisspeptin receptor systems in ovarian granulosa and cumulus cells. <b>2020</b> , 114, 869-878		9
600	Longitudinal Description of Gonadal Function in Sickle-cell Patients Treated With Hematopoietic Stem Cell Transplant Using Alkylator-based Conditioning Regimens. <b>2020</b> , 42, e575-e582		4
599	The comparison of evaluative effectiveness between antral follicle count/age ratio and ovarian response prediction index for the ovarian reserve and response functions in infertile women. <b>2020</b> , 99, e21979		4
598	The best execution of the DuoStim strategy (double stimulation in the follicular and luteal phase of the same ovarian cycle) in patients who are poor ovarian responders. <b>2020</b> , 18, 102		4
597	Safety and effectiveness of acupuncture for POSEIDON patients in IVF/ICSI: A protocol for systematic review and meta-analysis. <b>2020</b> , 99, e22768		1
596	Characteristics of the IVF Cycle that Contribute to the Incidence of Mosaicism. <b>2020</b> , 11,		2

595	Anti-Müllerian hormone and antral follicle count differ in their ability to predict cumulative treatment outcomes of the first complete ovarian stimulation cycle in patients from POSEIDON groups 3 and 4. <b>2020</b> , 46, 1801-1808	1
594	Conversion of in vitro fertilization cycles to intrauterine inseminations in patients with a poor ovarian response: Risk of multiple pregnancies. <b>2020</b> , 49, 101831	
593	Effectiveness of the flexible progestin primed ovarian stimulation protocol compared to the flexible GnRH antagonist protocol in women with decreased ovarian reserve. <b>2020</b> , 1-7	5
592	Cumulative live-birth, perinatal and obstetric outcomes for POSEIDON groups after IVF/ICSI cycles: a single-center retrospective study. <b>2020</b> , 10, 11822	5
591	Analysis of IVF/ICSI-FET Outcomes in Women With Advanced Endometriosis: Influence on Ovarian Response and Oocyte Competence. <b>2020</b> , 11, 427	7
590	Corifollitropin alfa for poor responders patients, a prospective randomized study. <b>2020</b> , 18, 67	1
589	FTIR Spectroscopy to Reveal Lipid and Protein Changes Induced on Sperm by Capacitation: Bases for an Improvement of Sample Selection in ART. <b>2020</b> , 21,	6
588	Testing and interpreting measures of ovarian reserve: a committee opinion. <b>2020</b> , 114, 1151-1157	30
587	Comparative Effectiveness of Mild or Conventional GnRH-Antagonist Protocols for Ovarian Stimulation in Poor Responders (Poseidon Group 4). <b>2020</b> , 2,	
586	Embryo incubation by time-lapse systems versus conventional incubators in Chinese women with diminished ovarian reserve undergoing IVF/ICSI: a study protocol for a randomised controlled trial. <b>2020</b> , 10, e038657	1
585	Update on the management of poor ovarian response in IVF: the shift from Bologna criteria to the Poseidon concept. <b>2020</b> , 14, 2633494120941480	5
584	Freeze-all versus fresh blastocyst transfer strategy during in vitro fertilisation in women with regular menstrual cycles: multicentre randomised controlled trial. <b>2020</b> , 370, m2519	34
583	Does coenzyme Q supplementation improve fertility outcomes in women undergoing assisted reproductive technology procedures? A systematic review and meta-analysis of randomized-controlled trials. <b>2020</b> , 37, 2377-2387	10
582	The effect of growth hormone supplementation in poor ovarian responders undergoing IVF or ICSI: a meta-analysis of randomized controlled trials. <b>2020</b> , 18, 76	10
581	The role of diet in unexpected poor response to ovarian stimulation: a cross-sectional study. <b>2020</b> , 41, 874-883	2
580	The continuum of ovarian response leading to BIRTH, a real world study of ART in Spain. <b>2020</b> , 6, 13	2
579	The significance of FMR1 CGG repeats in Chinese women with premature ovarian insufficiency and diminished ovarian reserve. <b>2020</b> , 18, 82	1
578	Predicting the chance on live birth per cycle at each step of the IVF journey: external validation and update of the van Loendersloot multivariable prognostic model. <b>2020</b> , 10, e037289	0

577	Follicular flushing leads to higher oocyte yield in monofollicular IVF: a randomized controlled trial. <i>Human Reproduction</i> , <b>2020</b> , 35, 2253-2261	5-7	17
576	Cutting the ovarian surface improves the responsiveness to exogenous hormonal treatment in aged mice. <b>2020</b> , 19, 415-424		2
575	Early ovarian ageing: is a low number of oocytes harvested in young women associated with an earlier and increased risk of age-related diseases?. <i>Human Reproduction</i> , <b>2020</b> , 35, 2375-2390	5-7	6
574	SAY NO to mild ovarian stimulation for all poor responders: it is time to realize that not all poor responders are the same. <i>Human Reproduction</i> , <b>2020</b> , 35, 1964-1971	5-7	7
573	LH supplementation of ovarian stimulation protocols influences follicular fluid steroid composition contributing to the improvement of ovarian response in poor responder women. <b>2020</b> , 10, 12907		6
572	The Conundrum of Poor Ovarian Response: From Diagnosis to Treatment. <b>2020</b> , 10,		5
571	Growth hormone alleviates oxidative stress and improves the IVF outcomes of poor ovarian responders: a randomized controlled trial. <b>2020</b> , 18, 91		7
570	Effect of acupuncture on women with poor ovarian response: a study protocol for a multicenter randomized controlled trial. <b>2020</b> , 21, 775		0
569	Stress Management during the Intracytoplasmic Sperm Injection Cycle May Slow Down First Embryo Cleavage and Accelerate Embryo Compaction: A Pilot Randomized Controlled Trial. <b>2021</b> , 90, 119-126		1
568	Affected Ovary Relative Volume: A Novel Sonographic Predictor of Ovarian Reserve in Patients with Unilateral Endometrioma-A Pilot Study. <b>2020</b> , 9,		0
567	Cellular, Extracellular and Extracellular Vesicular miRNA Profiles of Pre-Ovulatory Follicles Indicate Signaling Disturbances in Polycystic Ovaries. <b>2020</b> , 21,		8
566	New perspectives on the genetic causes of diminished ovarian reserve and opportunities for genetic screening: systematic review and meta-analysis. <b>2020</b> , 1, 1-15		1
565	Clinical Application of AMH Measurement in Assisted Reproduction. <b>2020</b> , 11, 606744		2
564	âWhen All Seems LostâThe Ultralong Estrogen Priming (ULEP) Cycle Offers Good Pregnancy Outcomes in Poor Responder Patients. <b>2020</b> , 02, 27-31		
563	Low KLOTTHO level related to aging is associated with diminished ovarian reserve. <b>2020</b> , 114, 1250-1255		6
562	Evolution of serum Anti-Müllerian Hormone (AMH) level in young women treated with chemotherapy for breast cancer according to basal AMH level. <b>2020</b> , 254, 132-137		4
561	Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency. <b>2020</b> , 113, 1251-1260.e1		20
560	ESHRE guideline: ovarian stimulation for IVF/ICSI. <b>2020</b> , 2020, hoaa009		66

559	The relationship between H19 and parameters of ovarian reserve. <b>2020</b> , 18, 46		4
558	Cycle day 2 insulin-like growth factor-1 serum levels as a prognostic tool to predict controlled ovarian hyperstimulation outcomes in poor responders. <b>2020</b> , 113, 1205-1214		3
557	The performance of the Elecsys <sup>®</sup> anti-Müllerian hormone assay in predicting extremes of ovarian response to corifollitropin alfa. <b>2020</b> , 41, 29-36		2
556	Growth hormone cotreatment for poor responders undergoing in vitro fertilization cycles: a systematic review and meta-analysis. <b>2020</b> , 114, 97-109		19
555	Is there a difference in ovarian reserve biomarkers and ovarian response between the right and left ovaries?. <b>2020</b> , 41, 416-424		2
554	The addition of clomiphene citrate to ovarian stimulation protocols for poor responders. <b>2020</b> , 251, 136-140		2
553	Delay in IVF treatment up to 180 days does not affect pregnancy outcomes in women with diminished ovarian reserve. <i>Human Reproduction</i> , <b>2020</b> , 35, 1630-1636	5-7	27
552	Prediction of Successful Ovarian Protection Using Gonadotropin-Releasing Hormone Agonists During Chemotherapy in Young Estrogen Receptor-Negative Breast Cancer Patients. <b>2020</b> , 10, 863		5
551	Reactivating Ovarian Function through Autologous Platelet-Rich Plasma Intraovarian Infusion: Pilot Data on Premature Ovarian Insufficiency, Perimenopausal, Menopausal, and Poor Responder Women. <b>2020</b> , 9,		27
550	Does an association exist between menstrual cycle length within the normal range and ovarian reserve biomarkers during the reproductive years? A systematic review and meta-analysis. <b>2020</b> , 26, 904-928		8
549	Stop GnRH-Agonist Combined With Multiple-Dose GnRH-Antagonist Protocol for Patients With "Genuine" Poor Response Undergoing Controlled Ovarian Hyperstimulation for IVF. <b>2020</b> , 11, 182		2
548	Efficacy and safety of Dingkun pill for female infertility patients with low prognosis undergoing in vitro fertilization-embryo transfer: study protocol for a multicenter, double-blind, randomized, placebo-controlled trial. <b>2020</b> , 21, 550		3
547	Outcomes of fertilization-embryo transfer in women with diminished ovarian reserve after growth hormone pretreatment. <b>2020</b> , 36, 955-958		3
546	Interleukin 6 in follicular fluid reduces embryo fragmentation and improves the clinical pregnancy rate. <b>2020</b> , 37, 1171-1176		0
545	ICSI does not improve reproductive outcomes in autologous ovarian response cycles with non-male factor subfertility. <i>Human Reproduction</i> , <b>2020</b> , 35, 583-594	5-7	11
544	The birth of a baby with mosaicism resulting from a known mosaic embryo transfer: a case report. <i>Human Reproduction</i> , <b>2020</b> , 35, 727-733	5-7	31
543	Management Strategies for POSEIDON Group 2. <b>2020</b> , 11, 105		5
542	Acupuncture for premature ovarian insufficiency: a systematic review and meta-analysis. <b>2020</b> , 18, 24-32		0



541	ART Monitoring: An End to Frequent Clinic Visits and Needle Sticks?. <b>2020</b> , 39-53	1
540	Improvement of Pregnancy Rate and Live Birth Rate in Poor Ovarian Responders by Intraovarian Administration of Autologous Menstrual Blood Derived- Mesenchymal Stromal Cells: Phase I/II Clinical Trial. <b>2020</b> , 16, 755-763	8
539	Novel Physiology and Definition of Poor Ovarian Response; Clinical Recommendations. <b>2020</b> , 21,	11
538	Mild stimulation protocol vs conventional controlled ovarian stimulation protocol in poor ovarian response patients: a prospective randomized controlled trial. <b>2020</b> , 301, 1331-1339	11
537	Assessing the practice of LuPOR for poor responders: a prospective study evaluating follicular fluid cfDNA levels during natural IVF cycles. <b>2020</b> , 37, 1183-1194	7
536	Comparative study of assisted reproductive outcomes between young patients with occult premature ovarian insufficiency and advanced-age patients. <b>2020</b> , 48, 300060520934656	0
535	Dual-trigger improves the outcomes of in vitro fertilization cycles in older patients with diminished ovarian reserve: A retrospective cohort study. <b>2020</b> , 15, e0235707	12
534	Role of anti-Müllerian hormone and testosterone in follicular growth: a cross-sectional study. <b>2020</b> , 20, 101	8
533	Does Endometriosis Influence the Embryo Quality and/or Development? Insights from a Large Retrospective Matched Cohort Study. <b>2020</b> , 10,	14
532	Luteal phase stimulation versus follicular phase stimulation in poor ovarian responders: results of a randomized controlled trial. <b>2020</b> , 18, 9	6
531	Luteinizing Hormone Action in Human Oocyte Maturation and Quality: Signaling Pathways, Regulation, and Clinical Impact. <b>2020</b> , 27, 1223-1252	20
530	Commentary: Management Strategies for POSEIDON Groups 3 and 4. <b>2019</b> , 10, 920	2
529	Does thiol/disulfide homeostasis affect the number of metaphase 2 oocyte in the treatment of fertilization?. <b>2020</b> , 6, FSO452	0
528	Controlled Ovarian Stimulation Protocols Alter Endometrial Histomorphology and Gene Expression Profiles. <b>2020</b> , 27, 895-904	5
527	Testicular sperm extraction and intracytoplasmic sperm injection outcome in cancer survivors with no available cryopreserved sperm. <b>2020</b> , 37, 875-882	2
526	Salt-inducible Kinases Are Critical Determinants of Female Fertility. <b>2020</b> , 161,	1
525	DuoStim - a reproducible strategy to obtain more oocytes and competent embryos in a short time-frame aimed at fertility preservation and IVF purposes. A systematic review. <b>2020</b> , 125, 121-130	14
524	Mild versus conventional ovarian stimulation for IVF in poor responders: a systematic review and meta-analysis. <b>2020</b> , 41, 225-238	10

523	Preimplantation genetic testing for aneuploidy in poor ovarian responders with four or fewer oocytes retrieved. <b>2020</b> , 37, 1147-1154	7
522	Follicular Output Rate and Follicle-to-Oocyte Index of Low Prognosis Patients According to POSEIDON Criteria: A Retrospective Cohort Study of 32,128 Treatment Cycles. <b>2020</b> , 11, 181	8
521	What Is the Best Regimen for Ovarian Stimulation of Poor Responders in ART/IVF?. <b>2020</b> , 11, 192	7
520	Heterogeneity Among Poor Ovarian Responders According to Bologna Criteria Results in Diverging Cumulative Live Birth Rates. <b>2020</b> , 11, 208	7
519	Acupuncture for in vitro fertilization in women with poor ovarian response: a systematic review. <b>2020</b> , 9, 100395	11
518	Predictors of live birth rate in women with diminished ovarian reserve. <b>2020</b> , 150, 222-227	0
517	A novel mathematical model of true ovarian reserve assessment based on predicted probability of poor ovarian response: a retrospective cohort study. <b>2020</b> , 37, 963-972	5
516	Follicular flushing versus direct aspiration in poor responder IVF patients: a randomized prospective study. <b>2020</b> , 248, 118-122	2
515	Is ovarian response associated with adverse perinatal outcomes in GnRH antagonist IVF/ICSI cycles?. <b>2020</b> , 41, 263-270	6
514	How fixed versus variable gonadotropin dose during controlled ovarian stimulation could influence the management of infertility patients undergoing IVF treatment: a national Delphi consensus. <b>2021</b> , 37, 255-263	3
513	Mild versus conventional ovarian stimulation for IVF in poor, normal and hyper-responders: a systematic review and meta-analysis. <b>2021</b> , 27, 229-253	14
512	Automated anti-Mullerian hormone measurement: data review to provide insights and interpretation. <b>2021</b> , 37, 511-514	0
511	Assisted conception in women of advanced maternal age. <b>2021</b> , 70, 10-20	3
510	Effect of recombinant LH supplementation on cumulative live birth rate compared with FSH alone in poor ovarian responders: a large, real-world study. <b>2021</b> , 42, 546-554	2
509	The effect of polycystic ovary syndrome without hyperandrogenism on pregnancy-related outcomes: a retrospective cohort study. <b>2021</b> , 128, 1003-1010	5
508	Effects of Growth Hormone Supplementation on Poor Ovarian Responders in Assisted Reproductive Technology: a Systematic Review and Meta-analysis. <b>2021</b> , 28, 936-948	1
507	Evaluation of the effect of trans-vaginal ovarian needle punctures on women with polycystic ovary syndrome. <b>2021</b> , 50, 101937	1
506	Female age is associated with the optimal number of oocytes to maximize fresh live birth rates: an analysis of 256,643 fresh ART cycles. <b>2021</b> , 42, 669-678	1

505	The risk of poor ovarian response during repeat IVF. <b>2021</b> , 42, 742-747	2
504	Bone morphogenetic protein-2 enhances gonadotropin-independent follicular development via sphingosine kinase 1. <b>2021</b> , 85, e13374	3
503	Efficacy of the delayed start antagonist protocol for controlled ovarian stimulation in Bologna poor ovarian responders: a systematic review and meta-analysis. <b>2021</b> , 303, 347-362	1
502	A bibliometric analysis of obstetrics and gynecology articles with highest relative citation ratios, 1980 to 2019. <b>2021</b> , 3, 100293	6
501	Patients with higher anti-Müllerian hormone levels from POSEIDON group 4 benefit from GnRH-agonist long protocol: A retrospective study. <b>2021</b> , 257, 88-94	0
500	Investigating apoptotic, inflammatory, and growth markers in poor responders undergoing natural in vitro fertilization cycles: a pilot study. <b>2021</b> , 1489, 78-90	
499	Human Menopausal Gonadotropin Commenced on Early Follicular Period Increases Live Birth Rates in POSEIDON Group 3 and 4 Poor Responders. <b>2021</b> , 28, 488-494	2
498	Ovulation induction with high progesterone levels may be more suitable for elderly patients with low ovarian response. <b>2021</b> , 50, 101661	5
497	Oocyte recovery rates in flushing versus nonflushing during oocyte retrieval in assisted reproductive techniques. <b>2021</b> , 8, 36	
496	Cumulative Live Birth Rate and Cost-Effectiveness Analysis of Gonadotropin Releasing Hormone-Antagonist Protocol and Multiple Minimal Ovarian Stimulation in Poor Responders. <b>2020</b> , 11, 605939	3
495	How does pathology influence cumulative pregnancy rate in poor responder patients?. <b>2021</b> , 1, 23	
494	FMR1 expression in human granulosa cells and variable ovarian response: control by epigenetic mechanisms. <b>2021</b> , 27,	2
493	Type and dose of gonadotropins in poor ovarian responders: does it matter?. <b>2021</b> , 15, 26334941211024203	0
492	A successful case of pregnancy after hysteroscopic ablation to cesarean scar syndrome. <b>2021</b> , 37, 84-88	
491	Inhibition of the NLRP3 inflammasome prevents ovarian aging. <b>2021</b> , 7,	19
490	Human growth hormone use in poor ovarian response - caution and opportunities. <b>2021</b> , 15, 2633494121999420	
489	POSEIDON classification and the proposed treatment options for groups 1 and 2: time to revisit? A retrospective analysis of 1425 ART cycles. <b>2021</b> , 2021, hoaa070	0
488	The POSEIDON stratification - moving from poor ovarian response to low prognosis. <b>2021</b> , 25, 282-292	2

- 487 Recovery of uterine and ovarian function in patients with complete placenta previa after caesarean delivery: A retrospective study. **2021**, 100, e24196
- 486 Natural Cycle Results in Lower Implantation Failure than Ovarian Stimulation in Advanced-Age Poor Responders Undergoing IVF: Fertility Outcomes from 585 Patients. **2021**, 28, 1967-1973 2
- 485 Sperm DNA fragmentation on the day of fertilisation is not associated with assisted reproductive technique outcome independently of gamete quality. **2021**, 1-17 1
- 484 Identification of predictive factors for the probability of pregnancy following ovulation stimulation-intra-uterine insemination cycles in terms of female and male. **2021**, 47, 893-899 1
- 483 Efficacy of growth hormone supplementation with ultrashort GnRH antagonist in IVF/ICSI for poor responders; randomized controlled trial. **2021**, 60, 51-55 3
- 482 Luteal Phase Ovarian Stimulation versus Follicular Phase Ovarian Stimulation results in different Human Cumulus cell genes expression: A pilot study. **2021**, 18, 1600-1608 1
- 481 Double or dual stimulation in poor ovarian responders: where do we stand?. **2021**, 15, 26334941211024172 3
- 480 TEMPORARY REMOVAL: Growth hormone improves insulin-like growth factor 1 and steroid hormone levels in follicle fluid, expression of hormone receptors in granulosa cells, and in vitro fertilization outcomes of poor ovarian responders. **2021**,
- 479 Growth hormone supplementation during ovarian stimulation improves oocyte and embryo outcomes in IVF/PGT-A cycles of women who are not poor responders. **2021**, 38, 1055-1060 1
- 478 Clinical Applications of Serum Anti-Müllerian Hormone Measurements in Both Males and Females: An Update. **2021**, 2, 100091 3
- 477 Circulating microRNAs as candidate biomarkers for the ovarian response during in vitro fertilization. **2021**, 100, e24612 1
- 476 Prospects of Germline Nuclear Transfer in Women With Diminished Ovarian Reserve. **2021**, 12, 635370 4
- 475 Controlled ovarian hyperstimulation for poor ovarian responders undergoing in vitro fertilisation/intracytoplasmic sperm injection: a protocol for systematic review and Bayesian network meta-analysis. **2021**, 11, e039122 2
- 474 Outdoor air pollution and diminished ovarian reserve among infertile Korean women. **2021**, 26, 20 3
- 473 Clinical Outcomes of Frozen-Thawed Embryos Generated From Growth Hormone Stimulation in Expected Poor Responders. **2020**, 11, 608225
- 472 Future fertility of patients with zero oocytes yield in their first IVF cycle attempt. **2021**, 16, e0246889 0
- 471 Role of RGMc as a Neogenin Ligand in Follicular Development in the Ovary. **2021**, 9,
- 470 Improving Reporting of Clinical Studies Using the POSEIDON Criteria: POSORT Guidelines. **2021**, 12, 587051 3

469	AMH Highly Correlates With Cumulative Live Birth Rate in Women with Diminished Ovarian Reserve Independent of Age. <b>2021</b> , 106, 2754-2766		7
468	Effects of Intraovarian Injection of Autologous Platelet-Rich Plasma on Ovarian Rejuvenation in Poor Responders and Women with Primary Ovarian Insufficiency. <b>2021</b> , 28, 2050-2059		4
467	Higher chromosomal aberration frequency in products of conception from women older than 32 years old with diminished ovarian reserve undergoing IVF/ICSI. <b>2021</b> , 13, 10128-10140		1
466	miR-221-3p regulates apoptosis of ovarian granulosa cells via targeting FOXO1 in older women with diminished ovarian reserve (DOR). <b>2021</b> , 88, 251-260		6
465	Histone demethylases JHDM1D, PHF2 and PHF8 expression pattern in granulosa cells obtained from patients undergoing IVF procedure during short-term IVC. <b>2021</b> , 9, 1-7		0
464	Do we trust scientific evidence? A multicentre retrospective analysis of first IVF/ICSI cycles before and after the OPTIMIST trial. <i>Human Reproduction</i> , <b>2021</b> , 36, 1367-1375	5-7	2
463	Association of single-nucleotide polymorphisms in the ESR2 and FSHR genes with poor ovarian response in infertile Jordanian women. <b>2021</b> , 48, 69-79		0
462	Individualized Ovarian Stimulation for Normal and High Responders. <b>2021</b> , 1-13		
461	Comparison of in vitro fertilization cycles stimulated with 20 mg letrozole daily versus high-dose gonadotropins in Rotterdam Consensus ultra-poor responders: A proof of concept. <b>2022</b> , 156, 102-106		
460	Individualized Ovarian Stimulation in Patients with Advanced Maternal Age and Premature Ovarian Aging. <b>2021</b> , 14-29		
459	In vitro activation of cryopreserved ovarian tissue: A single-arm meta-analysis and systematic review. <b>2021</b> , 258, 258-264		0
458	Endometrial scratching for poor responders based on the Bologna criteria in ICSI fresh embryo transfer cycles: a preliminary retrospective cohort study. <b>2021</b> , 22, 47-52		
457	Therapeutic effect of prolonged testosterone pretreatment in women with poor ovarian response: A randomized control trial. <b>2021</b> , 20, 305-312		0
456	FSH dose is negatively correlated with number of oocytes retrieved: analysis of a data set with ~650,000 ART cycles that previously identified an inverse relationship between FSH dose and live birth rate. <b>2021</b> , 38, 1787-1797		3
455	Minimal ovarian stimulation is an alternative to conventional protocols for older women according to Poseidon's stratification: a retrospective multicenter cohort study. <b>2021</b> , 38, 1799-1807		0
454	Does the additional use of clomiphene citrate or letrozole for in vitro fertilization deserve more attention?. <b>2021</b> , 21, 275		4
453	Consecutive ovarian stimulation is beneficial in patients with a poor response to high-dose follicle-stimulating hormone. <b>2021</b> , 37, 995-999		
452	The status and comparison of ovarian reserve between fertile and infertile healthy Chinese women of reproductive age. <b>2021</b> , 100, e25361		0

451	Step-Down of FSH- Dosage During Ovarian Stimulation - Basic Lessons to Be Learnt From a Randomized Controlled Trial. <b>2021</b> , 12, 661707		3
450	Antral follicle count and anti-Müllerian hormone to classify low-prognosis women under the POSEIDON criteria: a classification agreement study of over 9000 patients. <i>Human Reproduction</i> , <b>2021</b> , 36, 1530-1541	5-7	3
449	A large observational data study supporting the PROsPeR score classification in poor ovarian responders according to live birth outcome. <i>Human Reproduction</i> , <b>2021</b> , 36, 1600-1610	5-7	0
448	Management of recurrent implantation failure: British Fertility Society policy and practice guideline. <b>2021</b> , 1-25		5
447	Euploidy rates of embryos in young patients with good and low prognosis according to the POSEIDON criteria. <b>2021</b> , 42, 733-741		1
446	Retrospective outcome in women aged 45 years and older undergoing natural cycle IVF treatment. <b>2021</b> , 43, 66-72		
445	Predictive Factors for Live Birth in Fresh Fertilization/Intracytoplasmic Sperm Injection Treatment in Poor Ovarian Reserve Patients Classified by the POSEIDON Criteria. <b>2021</b> , 12, 630832		0
444	Hormonal profile of patients with deep infiltrative endometriosis. <b>2021</b> , 39-43		
443	Can Inhibin B Reflect Ovarian Reserve of Healthy Reproductive Age Women Effectively?. <b>2021</b> , 12, 626534		3
442	Does endometrioma surgery affect assisted reproductive technologies cycle outcome in patients with decreased ovarian reserve diagnosed by Bologna criteria?. 228402652110121		
441	Does LH supplementation in poor responders affect granulosa cells apoptosis rate in ART? A prospective randomised controlled trial. <b>2021</b> , 1-6		
440	Corifollitropin alfa in different variants of ovarian response in assisted reproductive technology programmes: literature review. <b>2021</b> , 33-38		
439	Diminished ovarian reserve is associated with reduced euploid rates via preimplantation genetic testing for aneuploidy independently from age: evidence for concomitant reduction in oocyte quality with quantity. <b>2021</b> , 115, 966-973		4
438	Acupuncture for Poor Ovarian Response: A Randomized Controlled Trial. <b>2021</b> , 10,		1
437	The clinical outcomes of fresh versus frozen embryos transfer in women ≥40 years with poor ovarian response. <b>2021</b> , 64, 284-292		0
436	Evaluating different strategies for poor ovarian response management: a retrospective cohort study and literature review. <b>2021</b> , 1500, 93-111		0
435	The association between thrombophilic genes alterations and poor ovarian response in infertile women: a retrospective case-control study. <b>2021</b> , 1-6		0
434	Effect of bisphenol A on alterations of ICAM-1 and HLA-G genes expression and DNA methylation profiles in cumulus cells of infertile women with poor response to ovarian stimulation. <b>2021</b> , 11, 9595		2

433	Can repeat IVF/ICSI cycles compensate for the natural decline in fertility with age? an estimate of cumulative live birth rates over multiple IVF/ICSI cycles in Chinese advanced-aged population. <b>2021</b> , 13, 14385-14398	2
432	Vitamin D and anti-Müllerian hormone concentration in human follicular fluid individually aspirated from all patient follicles. <b>2021</b> , 1-5	1
431	ART outcomes following ovarian stimulation in the luteal phase:a systematic review and meta-analysis. <b>2021</b> , 38, 1927-1938	0
430	İtrasitoplazmik sperm enjeksiyonu (ICSI) uygulanan infertil kadınlarda gebelik başarısını etkileyen faktörlerin değerlendirilmesi.	
429	The patient with reduced ovarian reserve. <b>2021</b> , 159-165	
428	Association between Receptor Polymorphisms and Luteinizing Hormone Levels for Low Ovarian Reserve Infertile Women. <b>2021</b> , 18,	0
427	Four consecutive minimal ovarian stimulation (TetraStim) is a feasible alternative to increase the number of oocytes and improve live birth rates in poor responders who do not accept oocyte donation. <b>2021</b> , 37, 1003-1007	
426	Searching for female reproductive aging and longevity biomarkers. <b>2021</b> , 13, 16873-16894	5
425	The Role of Traditional Chinese Formula Ding-Kun Pill (DKP) in Expected Poor Ovarian Response Women (POSEIDON Group 4) Undergoing Fertilization-Embryo Transfer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. <b>2021</b> , 12, 675997	2
424	Emerging follicular activation strategies to treat women with poor ovarian response and primary ovarian insufficiency. <b>2021</b> , 33, 241-248	0
423	Comparison of Cumulative Live Birth Rates Between GnRH-A and PPOS in Low-Prognosis Patients According to POSEIDON Criteria: A Cohort Study. <b>2021</b> , 12, 644456	0
422	Poor response during ovarian stimulation. 271-278	
421	The couple with recurrent implantation failure. <b>2021</b> , 200-206	
420	A decision tree model for predicting live birth in FMR1 premutation carriers undergoing preimplantation genetic testing for monogenic/single gene defects. <b>2021</b> , 43, 680-686	1
419	The Impact of Intracytoplasmic Sperm Injection in Non-Male Factor Infertility-A Critical Review. <b>2021</b> , 10,	2
418	Live birth rate with double ovarian stimulation is superior to follicular phase ovarian stimulation per started cycle in poor ovarian responders. <b>2021</b> , 47, 2705-2712	
417	The Maribor consensus: report of an expert meeting on the development of performance indicators for clinical practice in ART. <b>2021</b> , 2021, hoab022	8
416	Potential roles of experimental reproductive technologies in infertile women with diminished ovarian reserve. <b>2021</b> , 38, 2507-2517	0

- 415 Double HCG trigger improves recovery of oocytes in women with a paucifollicular response to ovarian stimulation: A pilot study. **2021**, 0
- 414 Influence of Maternal Age and Ovarian Reserve on the Decision to Continue or to Cancel IVF Cycles in Patients with One or Two Large Follicles: a Dual Effect. **2021**, 1 0
- 413 Clinical applications of in vitro primordial follicle activation. **2021**, 18, 194-200
- 412 Association of bioavailable inhibin B and oocyte yield in controlled ovarian stimulation. **2021**, 2, 189-194 0
- 411 Reasons and Mechanisms of Recurrent Failed Implantation in IVF.
- 410 Development of an optimal protocol for isolation and purification of human granulosa cells in patients with different ovarian reserves. **2021**, 22, 938 2
- 409 Interplay Between mTOR and Hippo Signaling in the Ovary: Clinical Choice Guidance Between Different Gonadotropin Preparations for Better IVF. **2021**, 12, 702446 0
- 408 Patients With Deep Ovarian Suppression Following GnRH Agonist Long Protocol May Benefit From a Modified GnRH Antagonist Protocol: A Retrospective Cohort Study. **2021**, 12, 618580 1
- 407 The circulating alarin level was elevated in infertile women with poor ovarian reserve. **2021**, 37, 1128-1131 1
- 406 [Prognostic factors of live-birth after in vitro fertilization for unexplained infertility: A cohort study]. **2021**, 49, 601-607 1
- 405 Autotransplantation of the ovarian cortex after in-vitro activation for infertility treatment: a shortened procedure. *Human Reproduction*, **2021**, 36, 2134-2147 5-7 1
- 404 Prediction of Ovarian Follicular Dominance by MRI Phenotyping of Hormonally Induced Vascular Remodeling. **2021**, 8, 711810
- 403 Evaluation of Ovarian Reserve Tests and Age in the Prediction of Poor Ovarian Response to Controlled Ovarian Stimulation-A Real-World Data Analysis of 89,002 Patients. **2021**, 12, 702061 1
- 402 Efficacy of three COS protocols and predictability of AMH and AFC in women with discordant ovarian reserve markers: a retrospective study on 19,239 patients. **2021**, 14, 111 0
- 401 Variants Ala307Ala and Ser680Ser of 307 and 680 FSHr polymorphisms negatively influence on assisted reproductive techniques outcome and determine high probability of non-pregnancy in Caucasian patients. **2021**, 38, 2769-2779 1
- 400 Therapeutic Efficacy of Catheter-directed Ethanol Sclerotherapy and Its Impact on Ovarian Reserve in Patients with Ovarian Endometrioma at Risk of Decreased Ovarian Reserve: A Preliminary Study. **2021**,
- 399 Development and Validation of a Clinical Pregnancy Failure Prediction Model for Poor Ovarian Responders During IVF/ICSI. **2021**, 12, 717288 0
- 398 and AKT/mTOR Signaling in Human Granulosa Cells: Functional Interaction and Impact on Ovarian Response. **2021**, 10, 3



397	Corifollitropin alpha was not detrimental to follicular ovarian responsiveness measured by follicular output rate (FORT). <b>2021</b> , 1-7	
396	Prevalence and characteristics of patients declined from pursuing in vitro fertilization with autologous oocytes. <b>2021</b> , 38, 2679-2685	0
395	Biological and clinical effects of a resveratrol-based multivitamin supplement on intracytoplasmic sperm injection cycles: a single-center, randomized controlled trial. <b>2021</b> , 1-9	1
394	Impact of Ovarian Yield-Number of Total and Mature Oocytes Per Antral Follicular Count-On Live Birth Occurrence After IVF Treatment. <b>2021</b> , 8, 702010	0
393	The impact of indomethacin on the number of oocytes retrieved and IVF outcomes in patients with poor ovarian response. <b>2021</b> , 264, 266-270	
392	Testosterone does not improve ovarian response in Bologna poor responders: a randomized controlled trial (TESTOPRIM). <b>2021</b> , 43, 466-474	0
391	Planned oocyte cryopreservation in women with blepharophimosis-ptosis-epicanthus inversus syndrome: a case series. <b>2021</b> , 2, 332-337	1
390	Correlation Analysis Between Ovarian Reserve and Thyroid Hormone Levels in Infertile Women of Reproductive Age. <b>2021</b> , 12, 745199	2
389	Blastocyst euploidy rates in low-prognosis patients according to the POSEIDON criteria: a retrospective analysis of 3016 embryos.. <b>2021</b> ,	0
388	Comparison of Dydrogesterone and Medroxyprogesterone in the Progestin-Primed Ovarian Stimulation Protocol for Patients With Poor Ovarian Response. <b>2021</b> , 12, 708704	0
387	Pathways and factors regulated by bone marrow-derived stem cells in human ovarian tissue. <b>2021</b> , 116, 896-908	1
386	Comparison of the Cumulative Live Birth Rates of Progestin-Primed Ovarian Stimulation and Flexible GnRH Antagonist Protocols in Patients With Low Prognosis. <b>2021</b> , 12, 705264	0
385	The Exploration of Poor Ovarian Response-Related Risk Factors: A Potential Role of Growth Differentiation Factor 8 in Predicting Ovarian Response in IVF-ET Patient. <b>2021</b> , 12, 708089	0
384	The Use of Androgen Priming in Women with Reduced Ovarian Reserve Undergoing Assisted Reproductive Technology. <b>2021</b> , 39, 207-219	
383	Evaluation of intra-ovarian platelet-rich plasma administration on oocytes-dependent variables in patients with poor ovarian response: A retrospective study according to the POSEIDON criteria. <b>2021</b> , 19, 137	1
382	Fertility preservation in childhood and adolescent female tumor survivors. <b>2021</b> , 116, 1087-1095	4
381	Idiopathic early ovarian aging: is there a relation with premenopausal accelerated biological aging in young women with diminished response to ART?. <b>2021</b> , 38, 3027-3038	0
380	Live birth rates in different subgroups of poor ovarian responders according to Bologna and POSEIDON group classification criteria. <b>2021</b> , 50, 102169	

379	The Follicular Output Rate (FORT) as a method to evaluate transdermal testosterone efficacy in poor responders. <b>2021</b> , 25, 229-234	0
378	fshr and lhr mRNA expression in granulosa cells of poor responder. <b>2021</b> , 1725, 012057	
377	Comparing sequential vs day 3 vs day 5 embryo transfers in cases with recurrent implantation failure: randomized controlled trial. <b>2021</b> , 25, 185-192	0
376	Evaluation of follicular flushing with double lumen needle in patients undergoing assisted reproductive technology treatments. <b>2021</b> , 25, 272-275	1
375	Reconsidering strategies for poor responder patients. What do we know now? What is reasonable to expect from the future?. <b>2021</b> , 1, 44	
374	Expression of genes that regulate follicle development and maturation during ovarian stimulation in poor responders. <b>2021</b> , 42, 248-259	3
373	Fresh and cumulative live birth rates in mild versus conventional stimulation for IVF cycles in poor ovarian responders: a systematic review and meta-analysis. <b>2021</b> , 2021, hoaa066	5
372	Introduction of Female Reproductive Processes and Reproductive Diseases. <b>2021</b> , 1300, 23-38	0
371	Ovarian Rejuvenation Using Autologous Platelet-Rich Plasma. <b>2021</b> , 2, 15-27	4
370	Morphological and immunohistochemical characteristics of the endometrium state in patients with diminished ovarian reserve. <b>2021</b> , 27, 58	
369	Age-related decline in the expression of GDF9 and BMP15 genes in follicle fluid and granulosa cells derived from poor ovarian responders. <b>2021</b> , 14, 1	11
368	Association of FSHR, LH, LHR, BMP15, GDF9, AMH, and AMHR polymorphisms with poor ovarian response in patients undergoing in vitro fertilization. <b>2021</b> , 25, 439-446	0
367	Meta-analysis of GnRH-antagonists versus GnRH-agonists in poor responder protocols. <b>2021</b> , 304, 547-557	1
366	Pharmacogenomic Biomarkers of Follicle-Stimulating Hormone Receptor Malfunction in Females with Impaired Ovarian Response-A Genetic Survey. <b>2021</b> , 10,	1
365	Development of a Dynamic Diagnosis Grading System for Infertility Using Machine Learning. <b>2020</b> , 3, e2023654	3
364	Assisted reproductive techniques. <b>2014</b> , 1154, 171-231	56
363	Behandlung der Patientin mit geringem Ansprechen auf die ovarielle Stimulation. <b>2019</b> , 1-11	1
362	Behandlung der Patientin mit geringem Ansprechen auf die ovarielle Stimulation. <b>2020</b> , 401-411	1

361	The Role of LH in Controlled Ovarian Stimulation. <b>2015</b> , 171-196	3
360	Estrogen treatment in infertile women with premature ovarian insufficiency in transitional phase: a retrospective analysis. <b>2018</b> , 35, 475-482	3
359	Current Therapeutic Options for Controlled Ovarian Stimulation in Assisted Reproductive Technology. <b>2020</b> , 80, 973-994	4
358	Comparison of pregnancy rates for poor responders using IVF with mild ovarian stimulation versus conventional IVF: a guideline. <b>2018</b> , 109, 993-999	39
357	Membrane Estrogen Receptor (GPER) and Follicle-Stimulating Hormone Receptor (FSHR) Heteromeric Complexes Promote Human Ovarian Follicle Survival. <b>2020</b> , 23, 101812	15
356	Live birth rates of low prognosis patients according to POSEIDON criteria; A retrospective cohort study. <b>2020</b> , 49, 101817	2
355	Does the FMR1 gene affect IVF success?. <b>2019</b> , 38, 560-569	5
354	Cumulative live birth rate of low prognosis patients with POSEIDON stratification: a single-centre data analysis. <b>2020</b> , 41, 834-844	2
353	The ratio of exogenous Luteinizing hormone to Follicle stimulating hormone administered for controlled ovarian stimulation is associated with oocytes' number and competence. <b>2020</b> , 40,	2
352	Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis. <b>2020</b> , 26, 247-263	46
351	Ovarian biomarkers predict controlled ovarian stimulation for in vitro fertilisation treatment in Singapore. <b>2020</b> , 61, 463-468	3
350	Effect of Switching from a Progestin-Primed Ovarian Stimulation Protocol to a Modified Ultra-Long Protocol Among Women Who Had 1 Progestin-Primed Ovarian Stimulation (PPOS) Failure Verses Those Who Had 2 PPOS Failures. <b>2020</b> , 26, e918705	2
349	Correlation between luteinizing hormone receptor gene expression in human granulosa cells with oocyte quality in poor responder patients undergoing fertilization: A cross-sectional study. <b>2019</b> , 8, 16	1
348	Ovarian Features after 2 Weeks, 3 Weeks and 4 Weeks Transdermal Testosterone Gel Treatment and Their Associated Effect on IVF Outcomes in Poor Responders. <b>2014</b> , 18, 145-52	13
347	The Effect of Omega-3 on the Number of Retrieved Ova, Fertilization Rate, and Embryonic Grading in Subfertile Females Experiences Intracytoplasmic Sperm Injection Management Protocols. <b>2018</b> , 11, 2221-2232	1
346	Effect of dehydroepiandrosterone administration in patients with poor ovarian response according to the Bologna criteria. <b>2014</b> , 9, e99858	30
345	A Patient Friendly Corifollitropin Alfa Protocol without Routine Pituitary Suppression in Normal Responders. <b>2016</b> , 11, e0154123	12
344	Female adolescents and young women previously treated for pediatric malignancies: assessment of ovarian reserve and gonadotoxicity risk stratification for early identification of patients at increased infertility risk. <b>2021</b> , 34, 25-33	3

343	Ovarian stimulation for preimplantation genetic testing. <b>2019</b> , 157, R127-R142	2
342	A modern view on ovarian reserve in women of reproductive age with endometriomas (a review). <b>2017</b> , 23, 72	2
341	Influence of surgical treatment of ovarian endometriomas cysts on ovarian reserve in women of reproductive age. <b>2018</b> , 24, 71	3
340	DNA methylation-based age prediction and telomere length in white blood cells and cumulus cells of infertile women with normal or poor response to ovarian stimulation. <b>2018</b> , 10, 3761-3773	18
339	Tyrosine nitrations impaired intracellular trafficking of FSHR to the cell surface and FSH-induced Akt-FoxO3a signaling in human granulosa cells. <b>2019</b> , 11, 3094-3116	4
338	Efficacy and safety of recombinant human follicle-stimulating hormone in patients undergoing fertilization-embryo transfer. <b>2020</b> , 12, 4918-4930	3
337	Efficacies of different ovarian hyperstimulation protocols in poor ovarian responders classified by the POSEIDON criteria. <b>2020</b> , 12, 9354-9364	8
336	Assisted reproductive technique in women of advanced fertility age. <b>2018</b> , 70, 738-749	8
335	Double stimulation in the same ovarian cycle (DuoStim) is an intriguing strategy to improve oocyte yield and the number of competent embryos in a short timeframe. <b>2019</b> , 71, 372-376	14
334	Luteal phase stimulation and fertility: first outcomes. <b>2019</b> , 178,	1
333	The role of G-CSF in recurrent implantation failure: A randomized double blind placebo control trial. <b>2016</b> , 14, 737-742	18
332	Does intrauterine saline infusion by intrauterine insemination (IUI) catheter as endometrial injury during IVF cycles improve pregnancy outcomes among patients with recurrent implantation failure?: An RCT. <b>2016</b> , 14, 583-588	11
331	Letrozole+ GnRH antagonist stimulation protocol in poor ovarian responders undergoing intracytoplasmic sperm injection cycles: An RCT. <b>2017</b> , 15, 101-108	13
330	Pregnancy outcome of "delayed start" GnRH antagonist protocol versus GnRH antagonist protocol in poor responders: A clinical trial study. <b>2017</b> , 15, 231-238	6
329	Live Birth Rates in Poor Responders' Group after Previous Treatment with Autologous Platelet-Rich Plasma and Low Dose Ovarian Stimulation Compared with Poor Responders Used Only Low Dose Ovarian Stimulation Before in Vitro Fertilization. <b>2019</b> , 7, 3184-3188	15
328	Novel markers of human ovarian granulosa cell differentiation toward osteoblast lineage: A microarray approach. <b>2019</b> , 20, 4403-4414	7
327	Poor ovarian reserve. <b>2016</b> , 9, 63-9	38
326	Effective treatment protocol for poor ovarian response: A systematic review and meta-analysis. <b>2016</b> , 9, 70-81	38

325	Genetics of Female Infertility: Molecular Study of Newborn Ovary Homeobox Gene in Poor Ovarian Responders. <b>2019</b> , 12, 85-91	2
324	Preliminary Results of DHEA in Poor Responders in IVF. <b>2016</b> , 06, 396-403	4
323	Dual trigger with gonadotropin-releasing hormone and human chorionic gonadotropin for poor responders. <b>2018</b> , 19, 98-103	5
322	DHEA supplementation improves endometrial HOXA-10 mRNA expression in poor responders. <b>2017</b> , 18, 160-166	2
321	What should be the protocol selection after failure of in-vitro fertilization at normoresponder patients: Agonist or antagonist?. <b>2014</b> , 11, 198-202	1
320	A retrospective comparative study of prednisolone use in antagonist co-treated assisted reproductive technology cycles for patients with good prognosis. <b>2018</b> , 15, 147-151	3
319	The combination of dehydroepiandrosterone, transdermal testosterone, and growth hormone as an adjuvant therapy in assisted reproductive technology cycles in patients aged below 40 years with diminished ovarian reserve. <b>2015</b> , 12, 60-65	2
318	The effects of fresh embryo transfers and elective frozen/thawed embryo transfers on pregnancy outcomes in poor ovarian responders as defined by the Bologna criteria. <b>2015</b> , 12, 132-138	14
317	Comparison of long GnRH agonist versus GnRH antagonist protocol in poor responders. <b>2014</b> , 11, 203-206	2
316	Empty Follicle Syndrome: The Possible Cause of Occurrence. <b>2015</b> , 30, 417-20	8
315	Diminished Ovarian Reserve, Causes, Assessment and Management. <b>2013</b> , 4, 45-55	4
314	Impact of office hysteroscopy in repeated implantation failure: Experience of a single center. <b>2016</b> , 17, 197-200	6
313	Risk Factors Associated with Impaired Ovarian Reserve in Young Women of Reproductive Age with Crohn's Disease. <b>2020</b> , 18, 200-209	3
312	miR-4463 regulates aromatase expression and activity for 17 $\beta$ estradiol synthesis in response to follicle-stimulating hormone. <b>2020</b> , 47, 194-206	4
311	DHEA use to improve likelihood of IVF/ICSI success in patients with diminished ovarian reserve: A systematic review and meta-analysis. <b>2018</b> , 22, 369-374	10
310	Serum microRNA profiling for the identification of predictive molecular markers of the response to controlled ovarian stimulation. <b>2020</b> , 24, 97-103	1
309	Results of IVF-ICSI cycles in low responder patients: An observational study. <b>2021</b> , 8, 100109	
308	Ethnic and Sociocultural Differences in Ovarian Reserve: Age-Specific Anti-Müllerian Hormone Values and Antral Follicle Count for Women of the Arabian Peninsula. <b>2021</b> , 12, 735116	1


- 307 A decision tree analysis applied to women aged 43-45: who should be referred for ovum donation?. **2021**, 0
- 306 Early Follicular Phase Human Chorionic Gonadotropin Addition May Improve the Outcomes of Fertilization/Intracytoplasmic Sperm Injection in Patients With "Unpredictable" Poor Response to Gonadotropin-Releasing Hormone Antagonist Protocol. **2021**, 12, 739773
- 305 Associations of paternal serum dioxin-like polychlorinated biphenyl concentrations with IVF success: A pilot study. **2021**, 206, 112248 0
- 304 Early administration of gonadotropin-releasing hormone antagonist versus flexible antagonist ovarian stimulation protocol in poor responders: a randomized clinical trial. **2021**, 26,
- 303 Evaluation of GnRH antagonist pretreatment before ovarian stimulation in a GnRH antagonist protocol in normal ovulatory women undergoing IVF/ICSI: a randomized controlled trial. **2021**, 19, 158 0
- 302 Use of platelet-rich plasma in the treatment of infertility in poor responders in assisted human reproduction procedures. **2021**, 22, 1412 2
- 301 Recombinant luteinizing hormone supplementation in assisted reproductive technology: a review of literature. **2021**, 26,
- 300 Follicular waves in ontogenesis and female fertility. **2021**, 210, 104558 0
- 299 Patient-Tailored Approaches to Ovarian Stimulation in ART. **2013**, 137-153
- 298 Behandlung der Patientin mit schlechtem Ansprechen auf die ovarielle Stimulation. **2013**, 407-414
- 297 Clinical aspects of controlled ovarian stimulation with corifollitropin alfa in ART. **2014**, 23 1
- 296 Is It Possible to Predict the Outcome of IVF Treatment in Poor Response Patients?. **2014**, 04, 703-709
- 295 The Challenge of Improving IVF Results in Normogonadotrophic (Unexpected) Young Poor Ovarian Responders: The Predictive Value of a Flexible Treatment Protocol Based on the âBiophysical Profile of the Uterusâ. **2015**, 05, 654-664
- 294 In Patients with Only One or Two Oocytes, Is IVF-ET or ICSI Better?. **2015**, 111-117
- 293 The Role of Androgens in Controlled Ovarian Stimulation. **2015**, 157-170
- 292 Obesity and Ovarian Aging (Diminished Ovarian Reserve and Menopause). **2015**, 149-159
- 291 Supplementation with DHEA in Poor Responder Patients. **2015**, 119-127
- 290 Multifollicular Stimulation. **2015**, 139-168

- 289 Estrogen supplementation in art (a review). **2015**, 21, 48 3
- 288 Prediction of Poor Responders and Current Concepts in Management. **2015**, 271-286
- 287 Fertility at midlife. **2015**, 6, 99-100
- 286 Management of Poor Responders. **2016**, 29-37
- 285 IVF and Egg Donation: Special Considerations. **2016**, 125-136
- 284 Intrauterine Insemination Treatment Strategy for Women over 35 Years Old: Based on a Large Sample Multi-center Retrospective Analysis. **2016**, 129, 2873-2875
- 283 Mild Stimulation Protocols: Combination of Clomiphene Citrate and Recombinant FSH or HMG. **2017**, 237-247
- 282 The current view of natural fertility. **2017**, 17, 4 0
- 281 Mild Stimulation Protocol for Poor Ovarian Responders Undergoing IVF. **2017**, 249-255
- 280 GnRH Antagonist Protocol: Is It Effective for Expected Poor Ovarian Responders with Tubal Factor Undergoing IVF?. **2017**, 05, 57-63
- 279 Clinical analyses of successful and previously failed intracytoplasmic sperm injection cycle parameters in patients with poor ovarian reserve. **2017**, 14, 58-63
- 278 Aromatase inhibitors in "poor" ovarian responders undergoing in vitro fertilization. **2017**, 66, 169-175
- 277 Adjuvants Therapies for Women Undergoing IVF: Is There Any Evidence of their Safety and Efficacy? An Updated Mini-Review. **2017**, 7, 1
- 276 Comparison of corifollitropin alfa and daily recombinant follicle-stimulating hormone in poor responder patients undergoing in vitro fertilization cycles. **2017**, 14, 199-202
- 275 Evaluation of clinical outcomes of ivf after estrogen priming before controlled ovarian stimulation in patients with a poor response. **2018**, 24, 53
- 274 Use of Basal Serum Testosterone Level as Predictor for Poor Ovarian Response in Women with Unexplained Infertility Undergoing <i>In Vitro</i> Fertilization Cycle: Prospective Study. **2018**, 08, 1520-1531 0
- 273 Düşük Rezervli Hastalarda GnRH Antagonist/Letrozol Stimülasyon Protokolünün Kullanımına İlişkin Retrospektif ve Prospektif Çalışma Sonuçları ve Etkisi. **2018**, 44, 13-17
- 272 Investigating Prognostic Factors for Assisted Reproductive Technology Outcomes in Qadir-Mother and Child Hospital of Shiraz, Iran. **2018**, In Press,

- 271 Fecundaci3n in vitro e inyecci3n intracitopl3smica de un espermatozoide. **2018**, 54, 1-21
- 270 Role of Dehydroepiandrosterone Supplementation in Improving Intracytoplasmic Sperm Injection Outcome for Women with Expected Poor Ovarian Response. **2019**, 09, 353-362
- 269 Estimulaci3n ov3rica para fecundaci3n in vitro-inyecci3n intracitopl3smica de espermatozoides en los ciclos con presunci3n de alta respuesta (2017). **2019**,
- 268 Comparison of the effectiveness of various stimulation protocols in patients with reduced ovarian reserve. **2019**, 25, 91
- 267 Present and Future in Personalized Clinical and Laboratory Approaches to In Vitro Fertilization Procedures. **2019**, 99-105
- 266 GONADOTROPINS IN OVULATION INDUCTION. **2019**, 8, 1498-1502
- 265 Azalm3n over rezervi olan olgularda long GnRH Agonist, GnRH Antagonist ve Mikrodoz Flare-up Agonist protokollerinin IVF sonu lar 3zerine etkisi.
- 264 Trigger Agents and Post-trigger Testing. **2020**, 201-208
- 263 Introduction: The Scope of the Problem with Diminished Ovarian Reserve. **2020**, 3-11
- 262 Natural Cycle Approaches for ART. **2020**, 131-137
- 261 Gonadotropin-releasing hormone agonist flare-up versus Gonadotropin-releasing hormone antagonist protocols in poor responders undergoing Intra Cytoplasmic Sperm Injection ICSI.. 1-8
- 260 Triggering Final Follicular Maturation for IVF Cycles. **2020**, 141-150
- 259 Outcomes in poor responders treated with in vitro fertilization/intracytoplasmic sperm injection according to bologna criteria. **2019**, 47-50
- 258 Assisted Reproductive Technologies. **2020**, 263-284
- 257 Cumulative live birth rate after up to three consecutive embryo transfer cycles in women with poor ovarian response. **2020**, 47, 135-139
- 256 The Interaction of Female Age and Active Male Smoking has Negative Influence on Success Rates of the Fertilization Treatments. **2020**, 23, 57-62
- 255 Reintroducing serum FSH measurement during ovarian stimulation for ART.. **2021**,
- 254 Confrontment and solution to gonadotropin resistance and low oocyte retrieval in in vitro fertilization for type I BPES: a case series with review of literature. **2021**, 14, 143



- 253 Expectant Management Before In vitro Fertilization in Women Aged 39 or Above and Unexplained Infertility Does Not Decrease Live Birth Rates Compared to Immediate Treatment. **2021**, 1 0
- 252 Evaluation of growth hormone co-treatment in in vitro fertilization in patients responding better to the GnRH antagonist short protocol. **2020**, 24, 147-151
- 251 Inositols in reproductive medicine. **2020**, 23-34 1
- 250 IN-VITRO ACTIVATION OF OVARIAN FOLLICULAR RESIDUAL RESERVE. **2020**, 25-28
- 249 Analysis of factors associated with ovarian reserve in a group of poor responders to in vitro fertilization: A cross-sectional study. **2020**, 18, 1065-1072
- 248 The First Live Birth in Lithuania After Application of Preimplantation Genetic Testing. **2020**, 27, 76-83 0
- 247 Randomised controlled trial on the effect of clomiphene citrate and gonadotropin dose on ovarian response markers and IVF outcomes in poor responders. *Human Reproduction*, **2021**, 36, 987-997 5-7 4
- 246 Fecundaci3n in vitro (FIV) en ciclo natural: del origen de la FIV a la pr3ctica asistencial actual. **2022**, 49, 100719
- 245 Medically Assisted Reproduction and Autoimmunity. **2020**, 273-285
- 244 Long-term results of organ-sparing treatment of benign ovarian tumors in women of reproductive age. **2021**, 27, 84
- 243 Food Supplements and Hormonal Products to Improve Assisted Reproductive Technology Outcomes in Patients with Diminished Ovarian Reserve. **2020**, 63-74
- 242 AMH and Medically Assisted Reproduction. **2020**, 31-36
- 241 Perinatal and neonatal outcome in poor ovarian responders in assisted reproductive technology (ART) pregnancy. **2020**, 3, 40
- 240 Assessment of Ovarian Reserve and Its Implications on Fertility. **2020**, 21-30
- 239 A SWOT Analysis of Human- and Machine Learning- Based Embryo Assessment. **2020**, 8, 227466-227481 2
- 238 One-step surgery for activation of ovarian function in patients with premature ovarian insufficiency (POI) and «poor» ovarian response. **2020**, 26, 58
- 237 Expression of genes involved in neurogenesis, and neuronal precursor cell proliferation and development: Novel pathways of human ovarian granulosa cell differentiation and transdifferentiation capability in vitro. **2020**, 21, 1749-1760 4
- 236 Assisted Reproductive Technologies. **2020**, 1-22

- 235 Effects of Ethnicity on Ovarian Stimulation and Fertility Preservation. **2020**, 565-571
- 234 Predictive value of ovarian hormone-producing function assessment in poor responders undergoing assisted reproductive technologies. **2019**, 68, 7-18
- 233 Use of androgens and aromatase inhibitors in poor responders undergoing in vitro fertilization. **2019**, 68, 37-46
- 232  **2020**, 70-77
- 231 A 10-Year Perspective on the Utility of Three Adjuvants Often Used in IVF: Growth Hormone, Melatonin and DHEA. **2021**, 2, 155-162 0
- 230 Dual stimulation in unexpected poor responder POSEIDON classification group 1, sub-group 2a: A cross-sectional study. **2020**, 18, 465-470
- 229 The Benefits of Testosterone Therapy in Poor Ovarian Responders Undergoing In Vitro Fertilisation (IVF).
- 228 Evaluaci3n de la reserva ov3rica: pasado, presente y futuro. **2020**, 28, 77-88
- 227 Follicular fluid metabolome and cytokinome profiles in poor ovarian responders and the impact of dehydroepiandrosterone supplementation.
- 226 Poor responder hasta grubunda y3sek doz gonadotropine kar3etrozol ile d3 doz gonadotropinin kar3er3emas3-randomize, tek k3, prospektif 3l33ha.
- 225 REME D3NEM3DE KADINLARDA TSH D3ZEY3N3 YUMURTA REZERV3NE ETK3S3
- 224 Prediction and diagnosis of poor ovarian response: the dilemma. **2011**, 12, 241-8 18
- 223 The Concepts and Consequences of Early Ovarian Ageing: A Caveat to Women's Health. **2013**, 14, 3-7 5
- 222 Comparison of different ovarian hyperstimulation protocols efficacy in poor ovarian responders according to the Bologna criteria. **2014**, 7, 1128-34 22
- 221 Evaluation of serum anti-Mullerian hormone as a biomarker of early ovarian aging in young women undergoing IVF/ICSI cycle. **2014**, 7, 6245-53 11
- 220 Cut-Off Levels of Anti-Mullerian Hormone for The Prediction of Ovarian Response, In Vitro Fertilization Outcome and Ovarian Hyperstimulation Syndrome. **2015**, 9, 157-67 10
- 219 The assesment of follicular fluid presepsin levels in poor ovarian responder womenandits relationship with the reproductive outcomes. **2015**, 8, 9961-6 1
- 218 Association between individual ovarian dimensions with ovarian reserve indices. **2013**, 12, 616-24

217	Comparison Pregnancy Outcomes Between Minimal Stimulation Protocol and Conventional GnRH Antagonist Protocols in Poor Ovarian Responders. <b>2016</b> , 10, 35-42	19
216	Does intrauterine saline infusion by intrauterine insemination (IUI) catheter as endometrial injury during IVF cycles improve pregnancy outcomes among patients with recurrent implantation failure?: An RCT. <b>2016</b> , 14, 583-588	9
215	Outcome of one hundred consecutive ICSI attempts using patient operated home sonography for monitoring follicular growth. <b>2016</b> , 8, 141-146	4
214	The role of G-CSF in recurrent implantation failure: A randomized double blind placebo control trial. <b>2016</b> , 14, 737-742	17
213	Letrozole+ GnRH antagonist stimulation protocol in poor ovarian responders undergoing intracytoplasmic sperm injection cycles: An RCT. <b>2017</b> , 15, 101-108	12
212	Occult Form of Premature Ovarian Insufficiency in Women with Infertility and Oligomenorrhea as Assessed by Poor Ovarian Response Criteria. <b>2017</b> , 18, 361-367	3
211	Accumulation of embryos over 3 natural modified IVF (ICSI) cycles followed by transfer to improve the outcome of poor responders. <b>2019</b> , 11, 77-84	3
210	Optimization of The Cell Aggregates Method for Isolation and Purification of Human Granulosa Cells from Follicular Fluid. <b>2020</b> , 13, 339-345	2
209	Rescue Maturation in Polycystic Ovarian Syndrome Patients Undergoing Fertilization Treatment who Overrespond or Underrespond to Ovarian Stimulation: Is It A Viable Option? A Case Series Study. <b>2020</b> , 14, 137-142	
208	Evaluation of the Effects of Platelet-Rich Plasma on Follicular and Endometrial Growth: A Literature Review. <b>2021</b> , 25, 601-607	
207	Effect of dual trigger on reproductive outcome in low responders: a systematic PRISMA review and meta-analysis. <b>2021</b> , 1-9	
206	Metabolomic Profiling of Poor Ovarian Response Identifies Potential Predictive Biomarkers. <b>2021</b> , 12, 774667	1
205	Growth hormone for in vitro fertilisation (IVF). <b>2021</b> , 11, CD000099	0
204	Growth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria.. <b>2021</b> , 12, 790160	0
203	Evaluation of the Effects of Platelet-Rich Plasma on Follicular and Endometrial Growth: A Literature Review. <b>2021</b> , 25, 601-607	0
202	Effect of Antagonist Start Day on Cycle Outcomes in Poor Responders.. <b>2021</b> , 14, 400-405	
201	ART in Cancer Survivors. <b>2022</b> , 47-66	
200	Polycystic ovary syndrome phenotype does not have impact on oocyte morphology.. <b>2022</b> , 20, 7	0

- 199 Managing the Infertility Patient with Endometriosis. **2022**, 199-215
- 198 Reduced ovarian function in women with complex congenital heart disease. **2022**, 7, 100317 2
- 197 Independent Variables for Determining the Cumulative Live Birth Rates of Aged Patients with Polycystic Ovary Syndrome or Tubal Factor Infertility: A Retrospective Cohort Study.. **2021**, 12, 728051 0
- 196 Optimal individualization of patient-oriented ovarian stimulation in Japanese assisted reproductive technology clinics, a review for unique setting with advanced-age patients.. **2022**,
- 195 ART in Male Cancer Patients Including Sperm Donation. **2022**, 441-452
- 194 Differential transcriptional profiles of human cumulus granulosa cells in patients with diminished ovarian reserve.. **2022**, 1 0
- 193 Altered T lymphocyte subtypes and cytokine profiles in follicular fluid associated with diminished ovary reserve.. **2022**, e13522 1
- 192 POSEIDON 1 and 2: Probable Causes and Proposed Treatment Strategies? An Evidence-based Update. **2022**, 13, 23-27
- 191 Co-Administration of Clomiphene Citrate and Letrozole in Mild Ovarian Stimulation Versus Conventional Controlled Ovarian Stimulation Among POSEIDON Group 4 Patients.. **2021**, 12, 780392 0
- 190 Which is more predictive ovarian sensitivity marker if there is discordance between serum anti-Müllerian hormone levels and antral follicle count? A retrospective analysis.. **2022**, 1-6
- 189 Gestión de la lista de espera y criterios de priorización en los tratamientos de reproducción asistida en los centros del Sistema Nacional de Salud de España. **2022**, 9, 100113
- 188 Association between different dual trigger dosages and IVF results in patients with POSEIDON Group IV.. **2022**, 0
- 187 Poor Ovarian Response to Gonadotrophins in PCOS Women after Laparoscopic Ovarian Drilling.. **2022**, 58,
- 186 Use of a recombinant human follicle-stimulating hormone:recombinant human luteinizing hormone (r-hFSH:r-hLH) 2:1 combination for controlled ovarian stimulation during assisted reproductive technology treatment: A real-world study of routine practice in the Russian Federation.. **2022**,
- 185 Proteomic Analysis of the Alterations in Follicular Fluid Proteins During Oocyte Maturation in Humans.. **2021**, 12, 830691
- 184 Use of Triggers on in vitro Fertilization and Evaluation of Risk Factors for Sub-Optimal Maturation Rate.. **2022**,
- 183 Evaluation of Controlled Ovarian Stimulation Protocols in Patients with Normal and Low Ovarian Reserve: Analyses of miRNAs and Selected Target Genes Involved in the Proliferation of Human Cumulus Cells and Oocyte Quality.. **2022**, 23,
- 182 Effects of vitamin D supplementation on ovarian reserve markers in infertile women with diminished ovarian reserve.. **2022**, 101, e28796

181	Women in Advanced Reproductive Age: Are the Follicular Output Rate, the Follicle-Oocyte Index and the Ovarian Sensitivity Index Predictors of Live Birth in an IVF Cycle?. <b>2022</b> , 11,	0
180	[Controlled ovarian stimulation protocols in endometriosis patients: with antagonist or agonist?]. <b>2019</b> , 48, 165-173	2
179	The Role of Luteinizing Hormone in Ovarian Stimulation of IVF Programs (literature review). <b>2022</b> , 28, 129	
178	Outcomes After a Single Ovarian Stimulation Cycle in Women of Advanced Reproductive Age: A Retrospective Analysis.. <b>2022</b> , 13, 792159	
177	The effect of hysteroscopy and conventional curettage versus no hysteroscopy on live birth rates in recurrent in vitro fertilisation failure: a retrospective cohort study from a single referral centre experience.. <b>2022</b> , 1-5	0
176	[Comparison of oral dydrogesterone with micronized vaginal progesterone in fresh embryo transfert in IVF / ICSI].. <b>2022</b> ,	0
175	Cumulative live birth rates for low-prognosis women over 5 years or 9 frozen-thawed embryo transfer cycles.. <b>2022</b> , 22, 233	0
174	Regulation of antral follicular growth by an interplay between gonadotropins and their receptors.. <b>2022</b> , 1	1
173	Comparative analyses in transcriptome of human granulosa cells and follicular fluid micro-environment between poor ovarian responders with conventional controlled ovarian or mild ovarian stimulations.. <b>2022</b> , 20, 54	1
172	Biallelic mutations in PSMC3IP are associated with secondary amenorrhea: expanding the spectrum of premature ovarian insufficiency.. <b>2022</b> , 1	1
171	Early Cervical Lesions Affecting Ovarian Reserve and Reproductive Outcomes of Females in Assisted Reproductive Cycles.. <b>2022</b> , 12, 761219	1
170	Androgens and diminished ovarian reserve: The long road from basic science to clinical implementation. A comprehensive and systematic review with meta-analysis.. <b>2022</b> ,	0
169	Cholesterol uptake or trafficking, steroid biosynthesis, and gonadotropin responsiveness are defective in young poor responders.. <b>2022</b> ,	0
168	Ovarian reserve parameters and IVF outcomes in 510 women with poor ovarian response (POR) treated with intraovarian injection of autologous platelet rich plasma (PRP).. <b>2022</b> , 14,	3
167	Reliability of AMH and AFC measurements and their correlation: a large multicenter study.. <b>2022</b> , 1	0
166	Effect of rLH Supplementation during Controlled Ovarian Stimulation for IVF: Evidence from a Retrospective Analysis of 1470 Poor/Suboptimal/Normal Responders Receiving Either rFSH plus rLH or rFSH Alone.. <b>2022</b> , 11,	0
165	Transcriptome-wide N6-methyladenine methylation in granulosa cells of women with decreased ovarian reserve.. <b>2022</b> , 23, 240	0
164	Evolution of serum progesterone levels in the very early luteal phase of stimulated IVF/ICSI cycles post hCG trigger: a proof of concept study.. <b>2022</b> , 1	0

- 163 Follicular activation in women previously diagnosed with poor ovarian response: a randomized, controlled trial.. **2022**, 117, 747-755 0
- 162 Managing poor ovarian response in the patient with diminished ovarian reserve.. **2022**, 117, 655-656 0
- 161 Stimulation for low responder patients: adjuvants during stimulation.. **2022**, 1 1
- 160 Is it time to revisit Rotterdam?. **2022**, 0
- 159 Mild/moderate versus full stimulation.. **2022**, 117, 664-668 1
- 158 The effect of dual stimulation on ploidy rates in patients with poor ovarian response. **2021**, 5, 1139-1143
- 157 Co-treatment with letrozole during ovarian stimulation for IVF/ICSI: a systematic review and meta-analysis.. **2021**, 3
- 156 Cellular Processes in Human Ovarian Follicles Are Regulated by Expression Profile of New Gene Markers-Clinical Approach.. **2021**, 11,
- 155 Effect of dehydroepiandrosterone administration before IVF on the live birth rate in poor ovarian responders according to the Bologna criteria: a randomized controlled trial. **2021**, 1
- 154 What Does Unexpected Suboptimal Response During Ovarian Stimulation Suggest, an Overlooked Group?. **2021**, 12, 795254 0
- 153 Female parental consanguinity is associated with a reduced ovarian reserve.. **2021**,
- 152 Progesterin-Primed Ovarian Stimulation with Clomiphene Citrate Supplementation May Be More Feasible for Young Women with Diminished Ovarian Reserve Compared with Standard Progesterin-Primed Ovarian Stimulation: A Retrospective Study.. **2021**, 15, 5087-5097
- 151 Idiopathic early ovarian ageing: risk of miscarriage and chance of delivery following ART in a nationwide cohort study.. *Human Reproduction*, **2022**, 5-7
- 150 Estrogen valerate pretreatment with the antagonist protocol does not increase oocyte retrieval in patients with low ovarian response: a randomized controlled trial.. *Human Reproduction*, **2022**, 5-7
- 149 Does current ovarian endometrioma increase the time for DOR patients to reach live birth in IVF?. **2022**, 22, 324
- 148 Ovarian Follicular Growth through Intermittent Vaginal Gonadotropin Administration in Diminished Ovarian Reserve Women.. **2022**, 14, 1
- 147 Ovarian Stimulation in Difficult IVF Cases. **2022**, 109-118
- 146 Ovarian Stimulation in Poor Responders. **2022**, 101-108

- 145 The Predictive Levels of Serum Anti-Müllerian Hormone and the Combined Index of the Number of Retrieved Oocytes and Good-Quality Embryos in Advanced-Age Infertile Women.. **2022**, 2022, 4224417 0
- 144 Table\_1.docx. **2019**,
- 143 Image\_1.pdf. **2019**,
- 142 Table\_1.xlsx. **2019**,
- 141 Image\_1.JPEG. **2019**,
- 140 Image\_2.JPEG. **2019**,
- 139 Image\_3.JPEG. **2019**,
- 138 Image\_4.JPEG. **2019**,
- 137 Image\_5.JPEG. **2019**,
- 136 Table\_1.DOCX. **2019**,
- 135 Table\_2.DOCX. **2019**,
- 134 Data\_Sheet\_1.docx. **2020**,
- 133 Data\_Sheet\_2.docx. **2020**,
- 132 image\_1.tif. **2018**,
- 131 table\_1.docx. **2018**,
- 130 Anti-Müllerian hormone in the assessment of ovarian reserve: possibilities and limitations. **2022**, 22, 65
- 129 Whole ovary laparoscopic incisions improve hormonal response and fertility in extremely poor ovarian response patients.. **2022**, 0
- 128 Fertility after Curative Therapy for Sickle Cell Disease: A Comprehensive Review to Guide Care.. **2022**, 11, 5

- 127 Development of a predictive model for luteal phase oocyte retrieval in poor responders undergoing natural cycle IVF.. **2022**, 12, 7695 ○
- 126 Regulatory Role and Potential Importance of GDF-8 in Ovarian Reproductive Activity. **2022**, 13, ○
- 125 Mitochondrial dysfunction in cumulus cells is related to decreased reproductive capacity in advanced-age women. **2022**, ○
- 124 Consecutive versus concomitant follicle-stimulating hormone and highly purified human menopausal gonadotropin: A milder response but better quality. **2022**, 49, 135-141
- 123 Intraovarian Injection of Recombinant Human Follicle-Stimulating Hormone for Luteal-Phase Ovarian Stimulation during Oocyte Retrieval Is Effective in Women with Impending Ovarian Failure and Diminished Ovarian Reserve. **2022**, 10, 1312
- 122 The use of intraovarian injection of autologous platelet rich plasma (PRP) in patients with poor ovarian response and premature ovarian insufficiency. **2022**, 34, 133-137 ○
- 121 Oocyte recovery rates in flushing versus nonflushing during oocyte retrieval in assisted reproductive techniques. **2021**, 8, 36
- 120 Analysis of somatic and reproductive history in patients with prognostically poor response of the testicles to gonadotropin stimulation. **2021**, 42-47
- 119 EROSS study: effect of ovarian reserve on sexual satisfaction. 1-6
- 118 Are antral follicle count and serum anti-Mullerian hormone level, as reliable markers of ovarian reserve, affected by UV radiation?. 1-5
- 117 Which Factors Are Associated With Reproductive Outcomes of DOR Patients in ART Cycles: An Eight-Year Retrospective Study. 13, ○
- 116 Targeted Deletion of Mitofusin 1 and Mitofusin 2 Causes Female Infertility and Loss of Follicular Reserve.
- 115 Preliminary report of intra-ovarian injections of autologous platelet-rich plasma (PRP) in extremely poor prognosis patients with only oocyte donation as alternative: a prospective cohort study. ○
- 114 Female Infertility Is Associated with an Altered Expression Profile of Different Members of the Tachykinin Family in Human Granulosa Cells.
- 113 The effect of medication on serum anti-müllerian hormone (AMH) levels in women of reproductive age: a meta-analysis. **2022**, 22, 3
- 112 An audit of clinical outcomes following ovarian administration of platelet-rich plasma ( PRP ) in women with severe diminished ovarian reserve. ○
- 111 Transcriptional Networks Underlying a Primary Ovarian Insufficiency Disorder in Alligators Naturally Exposed to EDCs.
- 110 Autologous ovarian platelet rich plasma treatment improves oocyte and embryo quality: a before-after prospective study. **2022**, 36, 425-432



- 109 Basal serum level of 4-androstenedione reflects the ovaries' ability to respond to stimulation in IVF cycles: setting up a new reliable index of both ovarian reserve and response.
- 108 Impact of increasing antimüllerian hormone (AMH) level on IVF fresh transfer and live birth rate. **2022,** ○
- 107 The Relationship Between Embryo Development and Apoptotic Gene Expression in Cumulus Cells of Oocytes Collected from Patients with Poor Ovarian Response and Polycystic Ovary Syndrome. **2022,**
- 106 Pregnancy rate in IVF patients with unexpected poor response to ovarian stimulation. 1-6
- 105 A diagnosis of diminished ovarian reserve does not impact embryo aneuploidy or live birth rates compared to patients with normal ovarian reserve. **2022,** ○
- 104 Follicular fluid PlGF and IVF/ICSI outcomes among PCOS and normo-ovulatory women using different controlled hyperstimulation protocols: A prospective case-control study. **2022, 79, 104096**
- 103 The Essential Role of Body Weight in Adjusting Gn Dosage to Prevent High Ovarian Response for Women With PCOS During IVF: A Retrospective Study. 13, ○
- 102 Evaluating The Efficacy of Ovulation Stimulation with Intrauterine Insemination ( IUI ) in Women with Diminished Ovarian Reserve Compared to Women with Normal Ovarian Reserve.
- 101 Editorial: Diminished Ovarian Reserve and Poor Ovarian Response: Diagnostic and Therapeutic Management. 13, ○
- 100 Comparison of two ovarian stimulation protocols among women with poor response: A randomized clinical trial.
- 99 Clomiphene citrate priming increases sensitivity during ovarian stimulation in poor ovarian responders undergoing in vitro fertilization treatment: a retrospective cohort study. 1-7
- 98 Low Oocyte Maturity Rate and Asynchronous Follicle Development: Other Unnoticed Groups in the Bologna Criteria for Poor Responders?. **2022, 23, 216-219**
- 97 Age-specific random day serum anti-Müllerian hormone reference values for women of reproductive age in the general population: a large Chinese nationwide population-based survey. **2022,**
- 96 Usage and cost-effectiveness of elective oocyte freezing: a retrospective observational study. **2022, 20,** ○
- 95 Accumulated Vitrified Embryos Could Be a Method for Increasing Pregnancy Rates in Patients with Poor Ovarian Response. **2022, 11, 4940**
- 94 Development of a Model Predicting the Outcome of In Vitro Fertilization Cycles by a Robust Decision Tree Method. 13,
- 93 Investigation of the Predictive Factors of Diminished Ovarian Reserve in Women Aged Less Than 40 Years and Undergoing ICSI Cycle.
- 92 Keep trying or give up? the future fertility of patients undertaking their first in vitro fertilization with no available embryos.

- 91 The association of serum phthalate metabolites with biomarkers of ovarian reserve in women of childbearing age. **2022**, 242, 113909 ○
- 90 Transcriptional networks underlying a primary ovarian insufficiency disorder in alligators naturally exposed to EDCs. **2022**, 557, 111751 ○
- 89 Does the dose or type of gonadotropins affect the reproductive outcomes of poor responders undergoing modified natural cycle IVF (MNC-IVF)? **2022**, 278, 95-99 ○
- 88 A Clinician-Friendly Machine Learning System to Predict Ovarian Response and Deploy Individualized Ovarian Stimulation Strategies in IVF. ○
- 87 Shortened ovarian stimulation duration may not affect oocyte developmental competence: a retrospective study. ○
- 86 Relation of graphical follicle models to the cumulative live birth rate in GnRH-antagonist stimulation treatment cycles. ○
- 85 What to advise to patients with only one good quality blastocyst, PGT-A or not? Outcomes of 2064 cycles. ○
- 84 Correlation of oocyte number with serum anti-Müllerian hormone levels measured by either Access or Elecsys in fresh in vitro fertilization cycles. **2022**, 49, 202-209 ○
- 83 The Clinical Application of Growth Hormone and Its Biological and Molecular Mechanisms in Assisted Reproduction. **2022**, 23, 10768 ○
- 82 Live Birth Rates in Women Under 38 Years Old with AMH Level <math>\leq 1.2\text{ ng/ml}</math> in the First In Vitro Fertilization + / - Intracytoplasmic Sperm Injection: Retrospective Study and Arguments for Care. ○
- 81 Predicting IVF outcome in poor ovarian responders. **2022**, 22, ○
- 80 Higher probability of live birth after transdermal testosterone pretreatment in women with poor ovarian response undergoing IVF: a systematic review and meta-analysis. **2022**, ○
- 79 Association of follicle-to-oocyte index and clinical pregnancy in IVF treatment: A retrospective study of 4,323 fresh embryo transfer cycles. 13, ○
- 78 The use of testosterone-containing gel with reduced ovarian reserve in women with infertility in ART programs (IVF/ICSI). **2022**, 28, 39 ○
- 77 Clomiphene citrate mild stimulation improved follicular development outcomes in PCOS women with high luteinizing hormone and poor ovarian response: A case report. **2022**, 101, e31323 ○
- 76 Current Options to Lower the Cost of In Vitro Fertilization: A Comprehensive Review. **2022**, ○
- 75 Intracytoplasmic sperm injection cycle success in patients under 35 years old with diminished ovarian reserve plus severe male factor. ○
- 74 Flushing of the Follicles in Ovum Pick-Up Procedures Gives a Better Chance for Pregnancy in Low Ovarian Reserve Patients. ○

73	Fertility With Early Reduction of Ovarian Reserve. <b>2022,</b>	0
72	Assisted Reproductive Technology. <b>2023, 237-250</b>	0
71	Expression of long noncoding RNAs in the ovarian granulosa cells of women with diminished ovarian reserve using high-throughput sequencing. <b>2022, 15,</b>	1
70	Comparison of ART outcome in patients with poor ovarian response according to POSEIDON criteria. <b>2022, 12,</b>	0
69	Single-cell RNA-seq analysis and cell-cluster deconvolution of the human preovulatory follicular fluid cells provide insights into the pathophysiology of ovarian hyporesponse. 13,	0
68	Flushing of the Follicles in Ovum Pick-up Procedures Gives a Better Chance for Pregnancy in Low Ovarian Reserve Patients.	0
67	Investigation of the role of X chromosome inactivation and androgen receptor CAG repeat polymorphisms in patients with recurrent pregnancy loss: a prospective caseâcontrol study. <b>2022, 22,</b>	0
66	LH increases the response to FSH in granulosa-lutein cells from sub/poor-responder patients in vitro.	0
65	The earlier the initiation of gonadotropin in poor responders in luteal phase stimulation protocols, the better. 13,	0
64	Oocyte-specific disruption of adrenomedullin 2 gene enhances ovarian follicle growth after superovulation. 13,	0
63	âShort agonist stopâ protocol, an ovarian stimulation for poor responders in in vitro fertilization (IVF): A pilot study. 13,	0
62	IL-6/IL-10 and IL-17/IL-4 ratios associated with poor ovarian response in women undergoing in-vitro fertilization. <b>2023, 280, 68-72</b>	0
61	Effects of sequential cleavage and blastocyst embryo transfer on pregnancy outcomes in patients with poor ovarian response. <b>2023, 155, 103780</b>	0
60	HORMONAL STATUS OF PATIENTS WITH A PREDICTED WEAK RESPONSE OF THE OVARIES TO GONADOTROPIN STIMULATION. <b>2022, 75, 2374-2378</b>	0
59	The physiological sonographic features of the ovary in healthy subjects: a joint systematic review and meta-analysis by the Italian Society of Gynecology and Obstetrics (SIGO) and the Italian Society of Endocrinology (SIE).	0
58	TEMPORARY REMOVAL: ANTI-MÛLLERIAN HORMONE IS NOT ASSOCIATED WITH EMBRYO PLOIDY IN PATIENTS WITH AND WITHOUT INFERTILITY UNDERGOING IN VITRO FERTILIZATION WITH PREIMPLANTATION GENETIC TESTING. <b>2022,</b>	0
57	The role of growth hormone in assisted reproduction. 13,	0
56	Influence of Diminished Ovarian Reserve on Early Embryo Morphokinetics during In Vitro Fertilization: A Time-Lapse Study. <b>2022, 11, 7173</b>	0

- 55 Impact of Endocrine Disorders on IVF Outcomes: Results from a Large, Single-Centre, Prospective Study. ○
- 54 Progestin-primed ovarian stimulation protocol with or without clomiphene citrate for poor ovarian responders: a retrospective cohort study. **2022**, 22, ○
- 53 Copeptin: A potential marker for the prediction of poor ovarian reserve in the infertile women. **2022**, 19, 281-286 ○
- 52 Construction and validation of a clinical predictive nomogram for intraductal carcinoma of the prostate based on Chinese multicenter clinical data. 12, ○
- 51 Ovarian rescue in women with premature ovarian insufficiency (POI): facts and fiction. **2022**, ○
- 50 Association of ABO blood groups with ovarian reserve: a retrospective cohort study in Chinese Han women younger than 40 years with infertility. **2022**, 15, ○
- 49 Membrane estrogen receptor and follicle-stimulating hormone receptor. **2022**, ○
- 48 The Polymorphism Asn680Ser on the FSH Receptor and Abnormal Ovarian Response in Patients with Normal Values of AMH and AFC. **2023**, 24, 1080 ○
- 47 Two clinical case reports of embryonic mosaicism identified with PGT-A persisting during pregnancy as true fetal mosaicism. ○
- 46 Decreased GDF9 and BMP15 in follicle fluid and granulosa cells and outcomes of IVF-ET among young patients with low prognosis. ○
- 45 Treatment modalities for poor ovarian responders. **2023**, 17, 263349412211474 ○
- 44 Infertility Evaluation. **2023**, 87-92 ○
- 43 An online tool for predicting ovarian responses in unselected patients using dynamic inhibin B and basal antimüllerian hormone levels. 14, 1
- 42 Feasibility and efficiency of delayed ovarian stimulation and oocyte banking for fertility preservation after fertility-impairing treatment. ○
- 41 Diminished ovarian reserve is a risk factor for preeclampsia and placental malperfusion lesions. **2023**, ○
- 40 Follicular Fluid Components in Reduced Ovarian Reserve, Endometriosis, and Idiopathic Infertility. **2023**, 24, 2589 ○
- 39 The cost-effectiveness analysis of the GnRH antagonist protocol and GnRH agonist short protocol for patients with poor ovarian response undergoing IVF-ET: A retrospective study.. ○
- 38 Eight weeks of androgen priming by daily low-dose hCG injections before ICSI treatment in women with low ovarian reserve. ○

- 37 Development and validation of a live birth prediction model for expected poor ovarian response patients during IVF/ICSI. 14, ○
- 36 Workup of female infertility. **2023**, 31-39 ○
- 35 Mechanism of Guilu Erxian ointment based on targeted metabolomics in intervening in vitro fertilization and embryo transfer outcome in older patients with poor ovarian response of kidney-qi deficiency type. 14, ○
- 34 Features of gynecological pathology in women with infertility and pathology of the thyroid gland. **2022**, 68-72 ○
- 33 Effectiveness, Flexibility and Safety of Switching IVF to IVM as a Rescue Strategy in Unexpected Poor Ovarian Response for PCOS Infertility Patients. **2023**, 12, 1978 ○
- 32 Bioinformatic analysis confirms differences in circular RNA expression profiles of cumulus cells between patients with ovarian and peritoneal endometriosis-associated infertility. 14, ○
- 31 Embryonic arrest: causes and implications. Publish Ahead of Print, ○
- 30 Anti-Müllerian hormone and pregnancy after autologous hematopoietic stem cell transplantation for multiple sclerosis. **2023**, 18, e0284288 ○
- 29 Comparison of ovarian stimulation in follicular and luteal phases in an ovarian cycle (DuoStim) in patients with poor ovarian response. **2023**, 12, ○
- 28 m.4216 T > C polymorphism in JT cluster determines a lower pregnancy rate in response to controlled ovarian stimulation treatment. **2023**, 40, 671-682 ○
- 27 Effect of PFOA exposure on diminished ovarian reserve and its metabolism. **2023**, 21, ○
- 26 The effect of individual oocyte matched follicular fluid oxidant, antioxidant status, and pro- and anti-inflammatory cytokines on IVF outcomes of patients with diminished ovarian reserve. **2023**, 102, e32757 ○
- 25 Principles of controlled ovarian stimulation for assisted reproduction. **2023**, 33, 91-96 ○
- 24 Progestin primed double stimulation versus flexible GnRh antagonist protocol in poor responders. A randomized control study.. ○
- 23 Effectiveness of GnRH Agonist Short Protocol Versus GnRH Antagonist Protocol in POSEIDON Groups 3 and 4: a Retrospective Cohort Study. ○
- 22 Effects of Zishen Yutai Pills on in vitro Fertilization-Embryo Transfer Outcomes in Patients with Diminished Ovarian Reserve: A Prospective, Open-Labelled, Randomized and Controlled Study. **2023**, 29, 291-298 ○
- 21 Women have clinical aspects of infertility with thyroid pathology. **2023**, 30-34 ○
- 20 MicroRNAs in POI, DOR and POR. ○

- 19 The BISTIM study: a randomized controlled trial comparing dual ovarian stimulation (duostim) with two conventional ovarian stimulations in poor ovarian responders undergoing IVF. ○
- 18 Corifollitropin Alfa for Controlled Ovarian Stimulation in Assisted Reproductive Technologies: State of the Art. **2023**, 45, 043-048 ○
- 17 Initiating Dose of hMG in Clomiphene plus hMG regimen in aged patients with poor ovarian response: More is better?. ○
- 16 Clinical Application of Double Ovulation Stimulation in Patients with Diminished Ovarian Reserve and Asynchronous Follicular Development Undergoing Assisted Reproduction Technology. ○
- 15 Systematic review of acupuncture to improve ovarian function in women with poor ovarian response. 14, ○
- 14 Adherence to the Mediterranean diet and the risk of unexpected poor response to ovarian stimulation in IVF cycles. **2023**, ○
- 13 The HERA (Hyper-response Risk Assessment) Delphi consensus definition of hyper-responders for in-vitro fertilization. ○
- 12 Clinical outcomes after fresh versus frozen embryo transfer in women with advanced reproductive age undergoing in vitro fertilization: a propensity score-matched cohort study. 1-10 ○
- 11 A new insight into the impact of systemic lupus erythematosus on oocyte and embryo development as well as female fertility. 14, ○
- 10 The effect of the embryo pooling method on the cumulative live birth rate in poor ovarian responders according to the Bologna criteria. ○
- 9 What is the Optimal Number of Embryos to Transfer for Poseidon Group 1 and Group 2? A retrospective study. ○
- 8 Effect of serum progesterone on human chorionic gonadotropin trigger day / metaphase II oocyte ratio on pregnancy and neonatal outcomes in women undergoing ICSI cycle. **2023**, 23, ○
- 7 Ovarian Stimulation with FSH Alone versus FSH plus a GnRH Antagonist for Elective Freezing in an Oocyte Donor/Recipient Programme: A Protocol for a Pilot Multicenter Observational Study. **2023**, 12, 2743 ○
- 6 Human granulosa cells of poor ovarian responder patients display telomeres shortening. ○
- 5 Nonylphenol Exposure-Induced Oocyte Quality Deterioration Could be Reversed by Boric Acid Supplementation in Rats. ○
- 4 Effectiveness of letrozole in pituitary downregulated normogonadotrophic young women with an initial poor response. **2023**, 102, e33510 ○
- 3 Effectiveness and Safety of Recombinant Human Follicle-Stimulating Hormone (Follitropeâ) in Inducing Controlled Ovarian Stimulation in Infertile Women in Real-World Practice: a Prospective Cohort Study. ○
- 2 Evaluation of GnRH antagonist pretreatment before ovarian stimulation in a GnRH antagonist protocol in women with poor ovarian response undergoing IVF/ICSI: A retrospective propensity-score-matching study. ○

- 1 Dysregulation of steroid metabolome in follicular fluid links phthalate exposure to diminished ovarian reserve of childbearing-age women. **2023**, 330, 121730

o